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THE ROLE OF CENTRAL ACE2 AND Nrf2 IN SYMPATHO-EXCITATION: 
RESPONSES TO CENTRAL ANGIONTENSIN II 
 
Anyun Ma 
University of Nebraska, 2020 
 
Advisor: Irving H. Zucker, Ph.D. 
Sympatho-excitation is a key characteristic in cardiovascular diseases such as chronic 
heart failure (CHF) and primary Hypertension (HTN). Evidence suggests that increased 
sympathetic tone is closely related to activation of the Renin-Angiotensin-Aldosterone 
system (RAAS) in the central nervous system. An underlying mechanism for sympatho-
excitation is thought to be oxidative stress resulting from Angiotensin II (AngII) type 1 
receptor (AT1R) activation. Over the past several decades, pharmacological targeting of 
components of the RAAS have been used as standard therapy in CHF and HTN. However, 
additional therapeutic strategies are necessary to control these diseases. Oxidative stress 
is regulated, in part, by the balance between components of the RAAS and the ability of 
the system to scavenge oxygen radicals. Over the past decade, Nuclear factor E2-related 
factor 2 (Nrf2) has emerged as an important transcriptional regulator that maintains redox 
homeostasis by governing a broad array of antioxidant genes in response to oxidant stress. 
Central Nrf2 dysregulation has been found in animals with CHF and HTN. To determine if 
Nrf2 contributes to decreased antioxidant defense and increased sympathetic nerve 
activity (SNA) in CHF, we upregulated Nrf2 in the rostral ventrolateral medulla (RVLM) in 
C57BL/6 mice and evaluated their hemodynamic and sympathetic function in the CHF 
state. We found that (1) Nrf2 and two target proteins, NAD(P)H dehydrogenase [quinone] 
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1 (NQO1) and Heme oxygenase (HO-1) in the RVLM were significantly lower in CHF 
compared to Sham mice; (2) Urinary norepinephrine (NE) excretion in CHF mice was 
markedly reduced following Nrf2 upregulation; (3) CHF mice overexpressing Nrf2 
exhibited an enhancement in spontaneous baroreflex gain and a decrease in basal renal 
SNA. In an attempt to understand the antioxidant function of the RAAS we examined the 
role of Angiotensin converting enzyme 2 (ACE2) in a model of central AngII-induced HTN. 
Despite its direct enzymatic effect on AngII, ACE2 has been shown to reduce oxidative 
stress and to be sympatho-inhibitory. It has been demonstrated that animals with CHF 
exhibit increased Angiotensin converting enzyme (ACE) and decreased ACE2 in the 
RVLM. We hypothesized that overexpression of ACE2 in the brain reduces the 
sympathetic and blood pressure (BP) responses to central AngII by activation of Nrf2 and 
enhancing antioxidant enzyme expression. To illuminate the role of Nrf2 in the central 
regulation of SNA in response to central AngII, we assessed Nrf2 changes in the RVLM 
in SynhACE2 mice treated with ICV AngII infusion. Mice with central overexpression of 
ACE2 inhibited the pressor and sympathetic responses to central AngII. We found that 
Nrf2 was upregulated in the RVLM in SynhACE2 mice, and that pharmacological 
upregulation of central Nrf2 had a significant impact on BP in response to central AngII. 
Overall, the experiments described in this dissertation showed that selectively 
upregulating Nrf2 in the RVLM attenuates sympatho-excitation in CHF mice. We also 
describe a novel role of interplay between central AngII, ACE2 and Nrf2 in the regulation 
of sympatho-excitation in central HTN. While not definitive, these studies suggest a role 
for ACE2 and Nrf2 as targets for therapy in CHF and HTN. 
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ACE           angiotensin-converting enzyme  
ACE2         angiotensin-converting enzyme 2 
ACEIs        ACE inhibitors 
Ach            acetylcholine 
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CSAR         cardiac sympathetic afferent reflex 
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DMV          dorsal motor nucleus of the vagus  
EF              ejection fraction 
ELISA        Enzyme-Linked Immunosorbant Assay 
ERK           extracellular regulated kinase 
FS              fractional shortening 
HTN           hypertension 
HF              high-frequency  
HFpEF       heart failure with preserved ejection fraction  
HO-1          Heme oxygenase-1 
HR              heart rate 
HRV           Heart rate variability 
IABS-A       Induced Baroreflex Sensitivity under Anesthesia  
IBRS-C      Induced Baroreflex Sensitivity in the conscious state  
ICV             intracerebroventricular  
Keap1         Kelch-like ECH-associated protein 1 
LAD            left anterior descending 
LF               low-frequency  
LTRs          long terminal repeats  
LVEDP       left ventricular end-diastolic pressure  
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Neural control of the cardiovascular system 
It was not until the 1940s that the central “vasomotor” center was discovered[2]. The 
central cardiovascular pathways are regulated by two general mechanisms: feed forward 
central command and reflex effects[3]. Mechanisms involved in feed forward control 
include neurons residing in the forebrain and midbrain, such as dorsomedial 
hypothalamus (DMH), the paraventricular nuclei (PVN), medial prefrontal cortex (mPFC), 
insular cortex, and midbrain periaqueductal gray (PAG) [4]. Neurons from these areas 
project to lower level nuclei in the baroreflex circuitry. These pathways modulate the 
baroreceptor reflex and sympathetic function thus impacting the short term control of 
arterial pressure (AP) [4].  
Nuclei that are within the baroreflex circuitry on the other hand, include the nucleus tractus 
solitarius (NTS) in the dorsomedial medulla, cardiac vagal motoneurons in the nucleus 
ambiguous(NA), caudal ventrolateral medulla (CVLM), and the RVLM [4]. The RVLM 
contains epinephrine synthesizing C1 neurons and glutamatergic neurons which receive 
and integrate a variety of inputs from the brainstem and forebrain in regulating BP and 
mediating multiple reflexes. The A1 noradrenergic neurons, located in the general 
ventrolateral medulla, are thought to be involved in natriuretic responses through 
activating vasopressin-secreting neurons in the PVN [5, 6]. RVLM may also contain pH-
sensitive neurons that receive excitatory synaptic inputs from the retrotrapezoid nucleus 
(RTN) chemoreceptors. These chemoreceptors activate the respiratory pattern generator 
(RPG) which eventually excites the sympathoexcitatory neurons of the RVLM [7, 8]. 
In addition to these classical neurons involved in the circuitry mediating baroreflex 
regulation, neurons from other important areas are indirectly related to BP control via 
changes in osmolality and involvement of the central RAAS [4, 9, 10]. These nuclei 
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originate from the organum vasculosum lamina terminalis (OVLT) in the anterior wall of 
the third ventricle, PVN, subfornical organ (SFO), median preoptic nucleus (MnPO), and 
supraoptic nucleus (SON) of the hypothalamus.  These regions are involved in multiple 
autonomic and behavioral control including the regulation of vasopressin release and 
drinking behavior, and the maintenance of  salt and water balance[11, 12]. The most 
thoroughly studied central cardiopulmonary regions and a simplified schematic of the 






























Figure 1.1 Schematic diagram of important central nuclei involved in 
cardiovascular control and baroreflex loop. 
Upper: Blue areas are brainstem autonomic control centers: NTS, nucleus tractus 
solitarius; DMV, dorsal motor nucleus of the vagus; NA, nucleus ambiguous; RVLM, 
rostral ventrolateral medulla; CVLM, caudal ventrolateral medulla; IML, 
intermediolateral nucleus; RTN, retrotrapezoid nucleus. Areas in grey shows 
circumventricular organs that involve various neuroendocrine functions: SFO, 
subfornical organ; PVN, paraventricular nuclei; OVLT, organum vasculosum lamina 
terminalis; MnPO, median preoptic nucleus; SON, supraoptic nucleus. 
Lower: Pathways in the baroreceptor reflex control of the sympathetic outflow. The 
continuous arrow and the dashed arrows indicate a stimulatory synapse and bar-
headed lines an inhibitory synapse, respectively. The solid lines indicate the major 
connections which are well established by studies. 
 
Figure 2.1 Shematic diagram of important central nuclei involved in 
cardiovascular control and baroreflex loop. 
Upper: Blue areas are brainstem autonomic control centers: NTS, nucleus tractus 
solitarius; DMV, dorsal motor nucleus of the vagus; NA, nucleus ambiguous; RVLM, 
Figure 1.  1 Schematic 
diagram of important 
central nuclei involved 
in cardiovascular 
control and baroreflex 
loop. 
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Peripheral reflex mechanisms play a critical role in mediating and interacting between the 
SNA and the extracellular environment. Several pathways not only form their own 
feedback loop but also communicate with each other to control BP, fluid volume, oxygen 
tension and body temperature.  
The arterial baroreflex relies on BP sensing elements (mechanoreceptors) in the carotid 
sinus and aortic arch, that transduce arterial BP fluctuations into neural signals (sensory 
action potentials).  Afferent signals travel in the glossopharyngeal and vagal nerves to the 
NTS. Neural signals from the NTS project to the CVLM which inhibits the RVLM[4, 13], 
provoking changes in the sympathetic outflow and vasopressin release. Signals from the 
NTS also project to the parasympathetic neurons in the dorsal motor nucleus of the vagus 
(DMV) and the NA, thus completing a negative feedback loop to maintain BP by regulating 
cardiac output and vascular resistance.  
The cardiopulmonary baroreflex is initiated from primary neurons whose cell bodies reside 
in the nodose ganglia, with the nerve endings distributed in the heart, vena cava and 
pulmonary vasculature. They sense changes in central blood volume, send afferent 
signals to central nuclei in a similar pattern as the arterial baroreflex. The efferent effects 
are similar except that the cardiopulmonary baroreflex mainly adjusts orthostatic BP in 
response to blood volume changes, due to the high compliance of the areas where the 
sensory endings are embedded. This reflex has little effect on heart rate (HR), especially 
in humans [13]. 
Sympatho-excitation is primarily transduced at the tissue level by adrenergic receptors 
that are widely expressed in most organs, while parasympathetic innervation is mainly 
distributed to the heart, bronchi and gastrointestinal tract. Both sympathetic and 
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parasympathetic outflow can affect the sinoatrial (SA), atrioventricular (AV) nodes, and 
cardiomyocyte contraction, reciprocally determining HR and contractility. 
The arterial chemoreflex is initiated by chemoreceptors located in the carotid sinus (carotid 
body) and aortic arch. These sensors detect changes in arterial pH, partial pressure of 
oxygen (PaO2) and carbon dioxide (PaCO2). In addition to their primary role in regulating 
ventilation, chemoreflex afferent activity also mediates an increase in sympathetic tone 
during hypoxia[13].  
Chronic heart failure  
According to the American Heart Association (AHA) 2017 Heart Disease and Stroke 
Statistics, approximately 41.5 percent, or 102.7 million people in the US suffered from at 
least one form of cardiovascular disease (CVD) in 2015 [14]. Globally, CVD has long been 
the number one cause of death, accounting for an estimated 31.5% of all global deaths 
[14, 15]. CVD not only exerts a heavy toll on people’s health, but also accounts for a 
tremendous economic burden to society.  
The termCHF and congestive heart failure may be used interchangeably although they 
are not necessarily the same concept. Congestive heart failure is a syndrome 
characterized by fluid accumulation in the lungs or peripheral circulation, often the result 
of systolic heart failure where there is a reduced ejection fraction (EF), also known as 
HFrEF. Opposed to HFrEF, there is heart failure with preserved EF, so called HFpEF, 
which results from diastolic dysfunction. Both conditions can progress to a chronic stage, 
thus the term CHF[16].   
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CHF is usually the end result of CVD and afflicts around 5.8 million Americans and over 
23 million people worldwide as of 2015 [17, 18].  Although the incidence of CHF may have 
been decreased over time due to improved medical care, the absolute number of more 
than 550,000 newly diagnosed cases each year still reflects persisting difficulties in 
managing CHF [17].  
Symptoms and signs of CHF include dyspnea on exertion, orthopnea, exercise intolerance, 
refractory volume overload and fatigue [19]. Etiologies of CHF include ischemic heart 
disease, valvular disease, cardiomyopathy, HTN, diabetes mellitus and other idiopathic 
conditions. Current management for CHF depends on both causes and stage of the 
problem. Over the past decades, numerous medications have been used in the 
management of CHF, including diuretics, β1-adrenergic receptor blockers, calcium 
channel blockers, digoxin, ACE inhibitors (ACEIs) / AT1R blockers (ARBs). Yet, the only 
ones that have been shown to be unequivocally beneficial in improving survival rate are 
ACEIs and ARBs [20, 21]. Although these approaches have made significant progress in 
symptom control, the incident of CHF is still unacceptably high. Therefore, the quest for 
exploring new therapeutic targets in CHF is of paramount importance.  
Primary (Essential) HTN 
HTN is by far the most common primary diagnosis in office visits in the United States, and 
one of the top causes of morbidity worldwide [22]. According to the World Health 
Organization, there were an estimated 1.13 billion people worldwide with HTN in 2015. In 
the US, approximately 75 million American adults have HTN, yet only about half are under 
control [23].  
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The ACC/AHA 2017 updated guidelines redefined HTN as office systolic BP (SBP) values 
≥130 mmHg and/or diastolic BP (DBP) values ≥80 mmHg, further extending the 
prevalence of HTN in US adult population to approximately 46 percent [15,19]. Not only 
does HTN itself exert a huge economic burden, the overall negative consequences of HTN 
being a contributing factor to a variety of CVD such as stroke and heart failure puts an 
even larger burden on public health worldwide [24].  
95 percent of all HTN cases are primary, or essential HTN, which is high BP without a 
known cause [25]. Therefore, current management of HTN mainly focuses on symptom 
control. Pharmacologic therapy for HTN include the use of thiazide diuretics, calcium 
channel blockers, ACEIs and ARBs [26]. However, despite multiple management, around 
30 percent of all uncontrolled patients fall into the category of apparent treatment-resistant 
HTN in the United States [27]. Thus identifying new insights and targets for HTN treatment 
is still a high priority.    
Sympathetic overactivity 
In chronic HFrEF,  impaired left ventricular systolic function results in an inadequate 
cardiac output, which initially unloads peripheral baroreceptors thus increasing 
sympathetic flow in a negative-feedback manner in an attempt to restore cardiac output 
[28]. Although being compensatory at first, these responses eventually enter a vicious 
cycle that lead to further disease progression. In chronic HFpEF, in spite of the fact that 
some current reviews confirm a correlation between sympathoexciation and HFpEF, 
evidence on potential neurohormonal mechanisms in this syndrome are scarce[29, 30].     
Hypotheses for the central mechanisms relating to deteriorating cardiac function in CHF 
include both neural and humoral disturbances[31]. First is the altered set point theory, 
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stating that alterations in  baroreflex gain increases the set point for sympathetic outflow 
(i.e. less sympatho-inhibition). This has been demonstrated in the paced-canine model in 
our lab, which showed increased baroreceptor stimulation elicits a drop in plasma NE 
concentration in normal dogs whereas baroreceptor denervation had no effects on NE 
concentration in CHF [32]. Another important mechanism is an enhanced central AngII / 
AT1R system acting as a positive feedback cycle and exciting SNA, in part, through 
increased oxidative stress[33]. It has been shown that AT1R protein and mRNA were 
upregulated in the RVLM and the NTS in rabbits and rats with heart failure [34, 35].  
Given the fact that most heart failure develops from coronary artery disease that is 
exacerbated by chronic HTN and obesity, it is plausible to speculate that generalized 
sympathoexcitation in primary HTN may also play a causative role in disease progression. 
It has been widely agreed that in both human and animal models HTN altered autonomic 
balance leads to hemodynamic dysregulation [36]. Evidence to support this include 
findings of enhanced NE spillover from sympathetic nerve terminals in HTN patients and 
in normotensive individuals with a family history of HTN [37, 38]. In normotensive offspring 
of HTN subjects, people with a family history of HTN have lower parasympathetic 
modulation than those with a negative history [39]. Therefore, it is reasonable to believe 
that central sympathetic overdrive may act as the initial pathogenesis of primary HTN 
under the background of genetic predisposition and environmental stimuli. 
Central RAAS Activation  
Systemic vs Local RAAS 
In addition to the autonomic reflex control of the circulation, BP and fluid homeostasis are 
closely regulated by the RAAS. Decreases in renal perfusion pressure are “sensed” by  
the juxtaglomerular (JG) cells in the kidney and renin is secreted and released into 
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circulation. Under the catalysis of plasma renin, angiotensinogen produced by the liver is 
converted into Angiotensin I (AngI), which is subsequently converted to AngII by ACE. 
ACE is predominantly produced in the lungs [40]. AngII has multiple functions in restoring 
BP and fluid volume: 1) it is a potent vasoconstrictor activating the AT1R on the blood 
vessels; 2) AngII acts in the adrenal cortex and stimulates secretion of aldosterone, which 
in turn increases sodium and water reabsorption in the distal nephron; 3) AngII is capable 
of directly enhancing activity of the epithelial Na+ channel (ENaC) in the distal nephron 
thus stimulating sodium and water reabsorption. 4)  AngII also causes the release of 
vasopressin, or anti-diuretic hormone (ADH), from the pituitary gland and evokes thirst, 
and increased drinking behavior [40].  
In addition to the conventional concept of a circulating RAAS, there is a wealth of evidence 
indicating the existence of local RAAS in various organs including the heart, vasculature, 
kidney and brain [41]. In CHF patients, local cardiac AngII concentration is increased as 
well as its gradient across the heart [42]. Using angiotensinogen overexpression 
transgenic mice, Mazzolal et al. demonstrated that increased AngII synthesis in the 
myocardium triggered cardiac hypertrophy[43]. Local cardiac intracellular renin 
expression was found to be enhanced after myocardial infarction and was related to 
impairment of cell communication through enhancing gap junction permeability [44, 45]. 
In hypertensive animals, increased cardiac AngII is associated with enhanced 
inflammation, oxidative stress and cell death [41]. In vascular muscle cells, synthesis of 
all major components including angiotensinogen, ACE, AngII and renin have been shown 
[46]. Furthermore, De Mello et al. found that intracellular AngII in resistance vessels 
counteracts the vasoconstrictive effects of extracellular AngII, thus playing an important 
role in regulating vascular tone[47]. In the kidney, the intrarenal RAAS was assessed and 
was found that stimulation of local AT1Rs enhanced sodium reabsorption [48]. So far it 
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has been widely acknowledged that along with systemic RAAS, local RAAS plays a 
fundamental role in the pathogenesis of CVD. This has opened a window for target-
specific therapeutics aiming locally at individual components of the RAAS system.  
Central RAAS and HTN  
In 1961, Bickerton and Buckley demonstrated specific central RAAS actions in the dog[49]. 
In 1971, Jacques Genest’s laboratory discovered renin synthesis in dog brain[50]. 
Numerous studies in animal models have now identified all components of the RAAS in 
the CNS. The role of the RAAS in the brain has been examined extensively in transgenic 
animals and by using pharmacological approaches. The central RAAS is related to a 
variety of mechanisms that mediate multiple actions including cognition, 
neurodegeneration and most importantly, BP regulation[51]. Intracerebroventricular (ICV) 
infusion of AngII into rat lateral ventricle has been shown to significantly increase BP, 
vasopressin release, drinking response (polydipsia) and sympathetic outflow[52]. Injection 
of AngII into the rat NTS suppressed the baroreflex, which was reversed by the AT1R 
antagonist losartan[53]. Double transgenic mice expressing both human renin and 
angiotensinogen generated by Sigmund’s laboratory exhibited increased salt intake and 
arterial BP, which was blunted by ICV, but not intravenous (IV) losartan treatment[54]. 
These studies indicate that the RAAS in the brain affects BP control and electrolyte 
balance possibly through different neural pathways.  
An integrative review of the central mechanisms underlying HTN included a possible 
course in the pathogenesis of HTN[55]. In order to maintain a relatively stable BP, there 
needs to be both a control center that determines a set point and a center that helps 
stabilize BP around this set point[56]. The former is thought to be in the hypothalamus, 
especially the PVN and SON; the latter occurs in the medulla oblongata[56]. Systemically 
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administered ACE inhibitors normalize the set point and baroreceptor sensitivity (BRS).  
The BRS remains in the normal range even when BP is increased by phenylephrine 
infusion[57]. Although when ACE inhibitors are given peripherally, it is possible to act in 
the CNS as well through sites without an intact brain-blood barrier. These findings indicate 
that AngII may play an essential role in determining the BP set point. What activates the 
central RAAS is proposed to be increased salt intake which is prevalent in the modern diet. 
Increased vasopressin stimulated sympathetic outflow and oxidative stress triggered by 
central AngII, all lead to primary HTN [55].  
ACE/AngII/AT1R and ACE2/Angiotensin 1-7 (Ang1-7)/MasR  
Within the RAAS system there exist two major counteracting arms – the “ACE/AngII/AT1R” 
arm and the “ACE2/Ang1-7/Mas receptor (MasR)” arm. ACE, or kininase II, was first 
isolated in 1956 and found to be the enzyme converting AngI to AngII, and degrading the 
vasodilator bradykinin[58]. ACE exists in two forms – membrane-bound form as 
ectoenzymes conventionally found in pulmonary vascular endothelium and testicular 
epithelial cells, and shed soluble form that is derived from the membrane-bound form 
present in serum and other body fluids[59, 60]. The current consensus now indicate that 
ACE is expressed in virtually all endothelial cell types as well as in neurons, smooth 
muscle cells, adipocytes and immunocytes[61]. For decades, ACE inhibitors have been 
the first line therapy for many major cardiovascular diseases including HTN, myocardial 
infarction, and heart failure and have been shown to improve survival in these patients 
[62].  
ACE2 on the other hand, is a more recently discovered carboxypeptidase and is a 
homolog of ACE[63]. ACE2 was first reported to cleave AngI to Ang 1-9, but later studies 
found that ACE2 has a much higher efficiency in the hydrolysis of AngII to Ang 1-7[64], 
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which turned out to play a fundamental role in counteracting AngII effects in many 
cardiovascular diseases. Thus this so-called “good arm of the RAAS”, ACE2/Ang1-7/ 
MasR axis, has since been extensively studied[65]. Quantitative PCR analysis has shown 
that the ACE2 gene is widely expressed in most human organs including the heart, kidney, 
intestines and brain[66]. Xia et al. reported that ACE2 is widespread throughout the mouse 
brain cardiovascular control centers such as PVN, NTS, and RVLM[67].  
In both CHF and HTN, these two axes of the RAAS have been shown to play pivotal roles 
in modulating sympathoexcitatory and sympathoinhibitory reflexes. In previous work from 
our laboratory we have shown that rabbits with CHF exhibit increased ACE, AT1 receptor 
and decreased ACE2  expression in several central nuclei including the RVLM, the PVN 
and the NTS [61]. We also demonstrated that SNA was significantly reduced in CHF mice 
that overexpress ACE2 in the brain[68]. However, the mechanisms by which central ACE2 
reduces sympathetic outflow are not clear.  
Although it is plausible to presume the anti-sympathetic effects of ACE2 is the result of 
either AngII consumption or Ang 1-7 production, the exact action of the latter on SNA 
remains controversial. Potts et al. reported that microinjection of Ang 1-7 into the RVLM 
exhibited sympatho-excitatory effects in anesthetized rabbits [69]. This was later 
supported by Frontes et al. by bilateral microinjection of the MasR antagonist A-779 into 
the RVLM, which produced a significant fall in mean arterial pressure (MAP) and HR [70]. 
In another study, Silva et al. demonstrated that bilateral microinjections of A-779 into the 
PVN resulted in a significant decrease in RSNA [71]. However, the sympatho-inhibitory 
effect of Ang 1-7 has also been shown in several other studies. Gironacci et al. found that 
minced hypothalami from spontaneous hypertensive rat (SHR) incubated with Ang 1-7 
showed significantly attenuated NE release[72]. Similar results were obtained by Mirnela 
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et al. in vitro where Ang 1-7 inhibited the nerve stimulation-induced release of 
norepinephrine and neuropeptide Y from the mesenteric arterial bed [73].  
In the case of HTN, Sriramula et al.[74] showed attenuation of the pressor response to 
peripheral infusion of AngII in mice that overexpress ACE2 in the brain. The same group 
also showed that peripheral AngII infusion increased oxidative stress in the PVN and 
RVLM significantly more in ACE2 knockout mice compared to their non-transgenic 
littermates[75]. Using transgenic mice overexpressing ACE2 in the SFO, Feng et al. 
demonstrated that ACE2 prevents the AngII-mediated pressor and drinking responses 
through AT1 receptor downregulation [76].  
Oxidative Stress 
Oxidative Stress and its role in Cardiovascular Disease 
In 1954, Dr. Denham Harman from University of Nebraska Medical Center first proposed 
the ‘free radical theory of ageing’, hypothesizing “free radicals” as the cause of 
macromolecular degenerative process of aging[77]. Then the concept of “oxidative stress” 
was introduced into research and clinical field by Helmut Sies in 1985[78]. Oxidative stress 
was later defined as “an imbalance between oxidants and antioxidants in favor of the 
oxidants, leading to a disruption of redox signaling and control and/or molecular 
damage”[79]. Over the past three decades, multiple studies on oxidative stress in a variety 
of diseases have been carried out. The most widely studied abnormalities include 
neurocognitive impairment, CVD, kidney dysfunction, and endocrine abnormalities[80].  
Reactive oxygen species (ROS) contribute in a major way to cellular and tissue oxidative 
stress. Major exogenous sources of ROS include environemental chemical exposures, UV 
light, ionizing radiation, organic solvents, etc. The main source of endogenous ROS have 
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been identified as mitochondria, peroxisomes, plasma membrane, and intra/extracellular 
spaces[81]. Important ROS such as superoxide anion radical (O2•−) and hydroxyl radical 
(HO•) exert their destructive effects through DNA and RNA damage, lipid peroxidation, 
protein damage/modification, and carbohydrate degradation[82]. To combat oxidative 
stress, living organisms have evolved defense systems which utilize antioxidant enzymes 
such as superoxide dismutase (SOD), catalase (CAT), HO-1, NQO1, glutathione (GSH), 
vitamin C and vitamin E. In addition, several metal compounds such as Zn and Se 
compounds behave as antioxidants [83].  
Long lasting oxidative stress has been shown to be closely related to the development 
and progression of many cardiovascular diseases including HTN, congestive heart failure, 
atherosclerosis, and cardiomyopathies[79,80]. Common mechanisms of oxidative stress 
as a causative or promoting factors of these diseases involve the activation in NF-κB 
pathways and increased inflammation[81,82], modulation of redox sensitive proteins thus 
altering certain transcriptional activities[84], direct structural damage, and reduction of 
antioxidant systems efficiency[27].  
In CHF, both clinical and experimental studies have discovered evidence of enhanced 
oxidative stress[85]. In the periphery, increased ROS promotes CHF progression by 
mechanisms involving cardiac electrophysiological changes, myocardial remodeling and 
reducing myofilament calcium sensitivity[86]. These processes eventually lead to left 
ventricular (LV) dilatation and contractile dysfunction. In the CNS, excessive production of 
local ROS in the brain has been increasingly investigated and is being presumed by many 
to be a primary culprit in the progression of CHF. Lindley et al. in 2004 demonstrated that 
ICV injection of an adenoviral vector encoding superoxide dismutase (Ad-Cu/ZnSOD) 
significantly decreased the number of chronically activated neurons in PVN and SON in 
 31 
MI-induced HF mice[87]. Previous studies from our lab showed that NADPH-dependent 
O2•− production in the RVLM was significantly increased in the CHF state compared with 
a sham group[88].  
In HTN, ROS exert detrimental effects also through both systemic and central 
mechanisms. Nitric oxide (NO) is generated mainly in the endothelium. Increased local 
ROS such as O2•− rapidly degrade NO thereby promoting vasoconstriction[89]. ROS 
generated by activated nicotinamide adenine dinucleotide phosphate(NADPH) oxidase, 
(NOX) have been shown to be key factors that mediate AngII-induced HTN, possibly 
through upregulating intracelluar pro-inflammatory mediators and vascular smooth muscle 
cell (VSMC) growth[90].  All of these mechanisms may explain why many patients with 
HTN exhibit an increase in oxidative stress and a decrease in NO bioavailability in many 
tissues[91]. Experimental mouse models with genetic deficiencies in NOX1 have also 
shown to have lower BP compared to their wild type counterparts[92]. 
There is little question that the CNS contributes to CVD. Elevated oxidative stress within 
certain brain nuclei has been consistently shown in different animal models. For example, 
Campos et al. showed that the expression of NOX subunits (p47 phox and gp 91 phox) is 
elevated in the PVN and RVLM in rats with HTN [93]. Hirooka et al. observed that ROS 
production is markedly increased in the RVLM of HTN rats [94].  
Relation between Oxidative Stress, Sympathoactivation, and RAAS 
As mentioned above, the pathogenesis and progression of CHF and HTN are closely 
related to altered SNA, central RAS and oxidative stress. However, the underlying 
molecular mechanisms and the exact cause-and-effect relationships between these 
factors are still under investigation. Current evidence largely point towards the hypothesis 
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that in both situations, an activated RAAS signaling in the brain trigger sympathoexcitation, 
most likely through ROS mobilization [95-97].  
Following a myocardial infarction (MI), there is an increase in plasma AngII and 
aldosterone[98]. On the one hand, plasma AngII can cause increased BP though 
promoting renal sodium absorption and its direct vesoconstrictor effect; on the other hand, 
circulating AngII can enter the CNS via brain areas lacking an intact blood-brain-barrier, 
such as the SFO, to activate SNA which, in turn, enhances the effects of the circulating 
RAAS. Although this process may be most prominent during the acute phase post MI, 
chronically enhanced SNA is thought to result from a aldosterone-triggered 
neuromodulatory system that involves “endogenous ouabain” release[99]. The direct 
effect of “ouabain” is inhibition of Na+/K+-adenosine triphosphatase (Na+/K+-ATPase) in 
neuronal membranes, which lowers membrane potential thereby enhancing SNA. 
Elevated circulating aldosterone can also readily cross the blood-brain-barrier to 
accomplish the above process. 
Tan et al. found the binding density of ACE is significantly elevated in the PVN in MI-
induced heart failure[100]. Studies from our laboratory have shown elevated ACE protein 
in several brain regions including RVLM, PVN and NTS in CHF rabbits [101]. Our previous 
experiments also showed that the cardiac sympathetic afferent reflex (CSAR) sensitivity 
is enhanced in dogs with pacing-induced CHF and is normalized by ICV administered the 
AT1R antagonist, losartan[102, 103]. The CSAR is one of the contributing factors for 
sympathoexcitation in CHF. Therefore, the overall increased in SNA may at least in part, 
be attributed to increased CSAR sensitivity due to upregulated AT1R expression. This 
was later by a study where microinjection of AT1R mRNA antisense into the PVN 
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normalized the CSAR in rats with CHF [104]. Similar increase of AT1R expression was 
also found in the RVLM in  CHF in studies from our laboratory [105].   
Oxidative stress as a contributing factor that activates sympathoexcitation has been well 
accepted based on large amount of evidence. Zanzinger et al. observed that removal of 
extracellular O2•− by microinjection of SOD into the RVLM reduced SNA outflow [106]. 
Furthermore, many studies have indicated that the sympathoexcitation of the RAAS is 
through its promotion of ROS generation.  Gao et al. showed that NADPH-dependent O2•− 
production is significantly increased in the RLVM of CHF rabbits compared with that of 
sham rabbits; and the effect of AngII on RSNA in the two groups is blocked by 
pretreatment with tempol or apocynin (APO) [88]. Zimmerman et al. showed that the 
pressor effects of ICV-AngII were abolished by administration of AdMnSOD in the mouse 
brain[107]. Campese et al. later showed that both SOD mimetics tempol and PEG-SOD 
effectively abolished the effects of AngII on central and peripheral SNA[108]. It was further 
demonstrated that the specific mechanism of this AngII-AT1R-ROS signaling on SNA 
involves inhibition of the delayed rectifier potassium current (IKv)[109] and influx of 
extracellular Ca2+ in neural cells[110], thus altering neuronal excitability.    
The pathogenesis and progression of primary HTN involve similar mechanisms to those 
of CHF except for some differences in the triggering events. Although the origin of primary 
HTN is multifactorial including high salt intake, chronic hypoxia, vascular inflammation and 
so forth, a common pathogenic initiator most always involves sympathetic overdrive[111]. 
As one of the several most important mechanisms, increased central RAAS activity in 
primary HTN has been consistently supported by the literature. An innovative study from 
Reudelhuber’s lab demonstrated that restoration of AngII exclusively in the brain of 
angiotensinogen-deficient mice increases their BP[112]. Morimoto et al. illustrated that 
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glia- and neuron-specific overexpression of AngII increases BP, polydipsia, and salt 
preference in mice[113]. These studies combined suggest that centrally derived AngII is 
a critical determinant in the development of HTN. In humans, an increase in vascular O2•−, 
H2O2 and a decrease in NO synthesis have also been observed in hypertensive individuals 
[114, 115]. There is increasing evidence supporting that increased ROS in HTN are 
contributed by both mitochondria nonenzymatic reactions and the increased intracellular 
NOX stimulated by RAAS activation[116, 117].  
Nrf2 
Since increased oxidative stress is thought to be a key molecular mechanism that links 
the RAAS and SNA, living organisms have developed a variety of antioxidant systems to 
prevent their harmful effects on cells. One of the most important and widely investigated 
regulators that help maintain redox balance is the Nrf2/ Kelch-like ECH-associated protein 
1 (Keap1) system[118]. Keap1 is a natural inhibitor of Nrf2 and normally keeps Nrf2 in the 
cytosol in the form of the Keap1-Nrf2 complex[119]. When activated by specific ROS or 
electrophiles, Nrf2 is dissociated from Keap1 and translocates into the nucleus, binding to 
antioxidant response elements and transactivating the expression of genes of a series of 
antioxidant enzymes. A previous study from our lab showed that selective Nrf2 gene 
deletion in the RVLM increases BP and sympathetic outflow in normal mice due to 
impaired antioxidant mechanisms [120].  
While an activated AngII/AT1R pathway is attributed to the upregulation of NOX in the 
RVLM in CHF[121], the mechanisms underlying downregulation of antioxidant enzymes 
remain to be elucidated. A key question is whether decreased Nrf2 in the RVLM in CVD 
characterized by sympatho-excitation is a result of increased RAAS activity. Feng et al 
reported that selective overexpression of ACE2 in the SFO prevents the pressor and 
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drinking reponses to ICV-AngII and downregulates AT1R[76]. In our preliminary studies, 
we measured Nrf2 expression in the RVLM and found Nrf2 to be elevated in transgenic 
mice overexpressing ACE2 in the brain, compared to their wild type littermates. This 
observation provided a suggestion for a potential Nrf2-RAAS interaction and serves as 
part of the rationale for our hypothesis. As shown in Fig 1.2, we propose that Nrf2 is 
important in maintaining the autonomic balance through its antioxidative property, Nrf2 
might also mediate the sympathoinhibitory effect of ACE2 in response to central RAAS 
activation. 
Overall hypotheses  
1. The role of RVLM Nrf2 modulation on sympathetic outflow in diseases such as CHF and 
HTN has not been well characterized. Therefore, we hypothesize that reduced Nrf2 
signaling in the RVLM contributes to impaired antioxidant defenses in CHF, leading to 
enhanced oxidative stress and sympathetic excitation. We further propose that 
upregulating Nrf2 will restore redox homeostasis in the RVLM in CHF, thus reducing the 
augmented sympathetic outflow. 
 
2. Given the fact that ROS is closely related to both the maladaptive effects of AngII/AT1R 
signaling and to the protective properties of ACE2 and Nrf2 in CVD, we explored the 
potential roles of RAAS-Nrf2 interaction in mediating central sympathetic activity. 
Therefore we hypothesize that overexpression of ACE2 in the brain reduces sympathetic 
outflow in response to chronic ICV-AngII infusion by reducing oxidative stress, in part, 








Figure 1. 2  Shematic diagram of ACE2 and Nrf2 signaling in RVLM neurons.  
It has been well established that the ACE/AngII/AT1R axis promotes sympathoexcitation in both 
CHF and HTN, and this axis is also pro-oxidative through activating NOX2. While both ACE2 and 
Nrf2 have anti-oxidative properties and exibit protective effects in various diseases, it is yet to 
be identified if this  arm of ACE2/Ang 1-7/MasR counteract the sympatho-excitatory effect of 
central AngII by upregulating Nrf2 and its downstream anti-oxidative defenses. 


















Figure 1. 1 Shematic diagram of ACE2 and Nrf2 signaling in RVLM neurons. 
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The overall goal of these experiments is to determine the mechanisms by which SNA is 
increased and antioxidant defenses are impaired in the RVLM in mice with CHF, and to 
determine the roles of ACE2 and Nrf2 in regulating SNA in HTN. Specifically, the goals of 
these experiments are defined by 3 objectives: 
Objective 1 (Chapter IV) 
To determine the effects of Nrf2 overexpression in the RVLM on sympathoexcitation in 
mice with CHF.  
 
Objective 2 (Chapter V) 
To determine the effects of ACE2 overexpression in the brain on pressor and metabolic 
responses to central AngII infusion.  
 
Objective 3 (Chapter VI) 






















Experiments were performed on 10- to 12-week-old mice. All the genotypes were on the 
C57BL/6 background. As described below, some early experiments were carried out in 
both male and female animals, but the majority were males. Some C57BL/6 mice were 
purchased from Charles River, Inc. (Wilmington, MA). In Objective 1, the Keap1 floxed 
(Keap1f/f) mice were originally obtained from Johns Hopkins University (laboratory of Dr. 
Shyam Biswal) and bred at The University of Nebraska Medical Center, Department of 
Comparative Medicine. Keap1f/f  mice contain LoxP sites flanking exons 2 and 3 of the 
Keap1 gene [12].  
In Objective 2, male transgenic mice with ACE2 overexpression in the brain (SynhACE2+/+ ) 
and their non-transgenic littermates were used. The SynhACE2+/+  mice were obtained 
from laboratory of Dr. Eric Lazartigues. Briefly, SynhACE2 fusion transgene was 
constructed and was microinjected into fertilized C57BL/6JxSJL/J(B6SJLF2) mouse 
embryos [122]. PCR genotyping was performed using the three-primer protocol[123]. Mice 
of genotype SynhACE2+/+ were crossed with wild type C57BL/6 mice to get the 
heterozygous SynhACE2+/-, which were further intercrossed to obtain SynhACE2-/- as 
control group. In Objective 3, the Nrf2 floxed mice (Nrf2f/f) were originally obtained from 
Dr. Shyam Biswal at the Johns Hopkins University [1] and bred in our facility. Selective 
Nrf2 knockdown was created by microinjection of Lenti-Cre-GFP virus into the RVLM 
bilaterally.  
All the mice were housed in standard polypropylene cages in a facility with a 12:12 hour 
light-dark cycle (6am – 6pm lights on) and fed with standard mouse chow (Harlan 
Laboratories, Indianapolis, IN) and allowed water ad libitum. All procedures were 
approved by the Institutional Animal Care and Use Committee at the University of 
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Nebraska Medical Center. Experiments were carried out consistent with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals and conformed with 
the ARRIVE Guidelines to the extent possible[124].  
Radiotelemetry implantation  
The mice were implanted with radiotelemetry units (PA-C10, Data Science International, 
Inc.; St Paul, MN) for BP and HR measurements in the conscious state. Briefly, under 2% 
isoflurane anesthesia, mice were placed in the supine position. After making a 10-mm 
incision in the ventral cervical area, the left carotid artery was identified, dissected, and 
separated from the left vagus nerve at the proximal location near the artery, followed by 
placing a cotton patch saturated with 2% lidocaine underneath the artery which was fully 
dilated during the process. The tip of the telemetry catheter (Fig 3.1) was then inserted 
into the carotid artery and advanced to the level of aortic arch. The transmitter was placed 
subcutaneously in the right lower abdominal area. Finally, the wound in the neck was 
closed with absorbable sutures (PERMA-HAND 6-0, Ethicon, Norderstedt, Germany). 
















Figure 3. 1 Radio telemetry (left) and schematic of telemetry catheterization 
into mouse right common carotid artery. 
Figure 3. 1Radio telemetry (left) and schematic of 




BP recording was performed at a sampling rate of 1 KHz using a PowerLab® data 
acquisition system (model 8S; ADInstruments, Inc.; Colorado Springs, CO). HR was 
derived from the arterial BP pulse. HR variability (HRV) and power spectral density (PSD) 
was assessed from the BP and HR using ADI software (Chart 8.0). High and low frequency 
cutoffs for power spectral analysis were 0.15 Hz to 1.5 Hz for low frequency (LF) and 1.5 
Hz to 5 Hz for high frequency (HF) as previously described[125]. 
Chronic heart failure model 
The CHF model was produced by permanent coronary artery ligation, as previously 
described[126]. Briefly, under anesthesia (∼2% isoflurane and 98% O2), mice were 
intubated and ventilated with a mouse ventilator (Mouse Ventilator MiniVent model 845, 
Hugo Sachs Elektronik; tidal volume: 150–250 μL; frequency: 200 breaths/min). The heart 
was exposed through a left thoracotomy at the fourth intercostal space. The anterior 
descending branch of the left coronary artery was permanently ligated with a 6-0 suture. 
Sham mice underwent thoracotomy and manipulation of the heart, but coronary artery 
ligation was not performed. To reduce acute mortality in the coronary ligated group, in 
postoperative care the mice were allowed to stay in the housing cage with supplemental 
100% oxygen and a heating pad set at 30–32 °C for 3 days or longer as needed. 










A) The suture was placed through the myocardium into the anterolateral left 
ventricle wall underneath the left anterior descending coronary artery, 1-3 mm from 
tip of the normally positioned left auricle. B) The left ventricle was cut open and 
spread on a flat plate. A well defined transmural scar was observed in the ischemic 
area as marked by the dashed line. 
A. B. 




At the fourth week post coronary ligation or sham surgery, mice were 
echocardiographically imaged on a Visual Sonics Vevo 3100 ultrasound using a 40 MHz 
probe under light isoflourane anesthesia (0.5–1%). 2D B-mode images were acquired in 
the long and short parasternal axis. M-Mode images were acquired at the level of the left 
ventricular papillary muscles. Left ventricular volumes and diameters were measured. 
Ejection fraction (EF) was calculated by a standard formula EF = [(LVEDV-
LVESV)/LVEDV] x 100. Fractional shortening (FS) was calculated as FS = [(LVEDD-
LVESD)/LVEDD] x 100. The echocardiographer was blinded as to the origin of the animal 
groups. 
Microinjection of lentiviral vector into the RVLM 
CamKIIa promoter (HIV-CamKIIa-GFP-Nrf2) driven Lentivirus encoding the Nrf2 gene 
was purchased from the Viral Vector Core, University of Iowa, IA. The Cytomegalovirus 
(CMV) promoter driven Lenti-GFP-Cre virus was purchased from Kerafast, Inc, Boston, 
MA. Lenti-GFP-Cre contains both 5′ and 3’ lentiviral long terminal repeats (LTRs) and all 
necessary elements for effective transduction and expression of GFP and Cre genes.  
The delivery of viruses into the bilateral RVLM  was performed on a mouse stereotaxic 
apparatus (SR-5M, NARISHIGE, Japan) with the mouse in prone position. The mouse 
was anesthetized with isoflurane (∼2%). Two small holes were made overlying the 
cerebellum with a sterile 18-gauge needle to locate RVLM  according to the following 
coordinates: 1.2 mm lateral to the midline, 5.3 mm ventral to the dorsal surface of the brain, 
1.9 mm caudal to lambda [127]. Viruses were injected bilaterally into the RVLM using a 
34-gauge needle attached to a microsyringe (Model 62 RN SYR, Hamilton Company, 
Reno, NV). Mice were left to recover for 2 weeks before recordings or physiological 
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experiments. RVLM targeting was confirmed by confocal immunofluorescence of GFP 
after euthanasia. The brain stem was removed and stored at −80°C for subsequent 
biochemical measurements. 
ICV infusion and implantation of osmotic minipump 
The mouse was placed on the stereotaxic apparatus with the skull exposed through a 
midline scalp incision. Under anesthesia, a small hole was drilled over the right cerebral 
ventricle using the following coordinates: 1.1 mm lateral from midline, 0.55 mm posterior 
to the bregma, and approximately 2.5 mm deep from the dorsal surface of the brain (Fig 
3.3). Then a small incision was made in the mouse back between the scapulae. Using a 
hemostat, a small pocket was made by spreading the subcutaneous connective tissues 
apart. For different experimental purposes, a 14-day or 7-day Alzet osmotic minipump  
(MODEL 1002, Durect Corporation, Cupertino, CA) was inserted into the pocket. The 
minipump was attached to a cannula (ALZET Brain Infusion Kit3) for the ICV infusion of 
artificial CSF (aCSF), AngII (A9525, Sigma-Aldrich), Ang1-7 (A9202, Sigma-Aldrich), or 
A-779 (SML1370, Sigma-Aldrich) at a rate of 0.25uL/hr (14-day pump) or 0.5uL/hr (7-day 







A. Atlas of mouse brain showing location of the RVLM (orange) in sagittal view. B. 
Osmotic pump and a cannula set inplanted in a mouse for ICV infusion. C. Methylene 







Figure 3. 3 Osmotic minipump implantation. 
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Renal Sympathetic Nerve Activity (RSNA) recordings 
Mice were anesthetized with isoflurane (2%) and were ventilated with room air after 
tracheal cannulation (tidal volume: 150 μL, frequency: 200 breaths/min)[128]. The right 
femoral artery and vein were dissected and separated from the femoral nerve for venous 
and arterial cannulation (Millar transducer). A bundle of the left renal sympathetic nerves 
was isolated in the retroperitoneal space through a left flank incision and placed on a pair 
of platinum-iridium recording electrodes. The nerve-electrode complex was covered with 
silicone gel (Kwik-Sil, WPI, Sarasota FL). The RSNA signal was amplified ( × 1000) and 
filtered (bandwidth: 30–3000 Hz) using a Grass P55C preamplifier, and input into a 
PowerLab® data-acquisition system, from which the signal was monitored, recorded, and 
saved using the LabChart® 7 software (AD Instruments, Inc. Colorado Sprngs, CO). 
BRS Analysis 
Spontaneous BRS (sBRS) in conscious mice was determined from the pulsatile BP 
signals based on the sequence technique[129], using HemoLab Software (Version 20.2, 
courtesy of Dr. Harald M. Stauss, University of Iowa). Individual sequences of increases 
or decreases in BP in mmHg (x-axis) and pulse interval in msec (y-axis) values were 
plotted and subjected to linear regression. The average of the slopes of all individual 
regression lines were then used as an index of baroreceptor-HR reflex sensitivity 
(ms/mmHg). 
Induced Baroreflex Sensitivity in the conscious state (IBRS-C) was evaluated by 
calculating the percent of the decline in HR from the maximal value within 30 min after 
intraperitoneal injection of phenylephrine (PE) (10 μg in 50 μl). 
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Induced Baroreflex Sensitivity under Anesthesia (IABS-A) was analyzed by logistic 
regression over the entire pressure range after PE administration. The values for BP and 
RSNA were acquired every 2 s from the threshold to the saturation points. A sigmoid 
logistic regression curve was fit to the data points using the following equation: 
RSNA =  !
"#$%&	[)(+!,-.)]
+ 𝐷,	 where A is the RSNA range, B is the slope coefficient, C is 
the pressure at the midpoint of the range (BP50), and D is the minimum RSNA. The peak 
slope (or maximum gain) was determined by taking the first derivative of the baroreflex 
curve and was calculated with the equation: Gain max = A(1) × A(2) × [1/4], where A(1) is 
the range and A(2) is the average slope. The mean values for each curve parameter were 
used to derive composite curves for each experimental group. 
Metabolic cage study 
In experiments where drinking and urine responses were measured, mice were housed 
individually in metabolic cages (Harvard Apparatus, Holliston, MA). Food and water were 
accessible ad libitum and all the mice were allowed to adapt to the metabolic cages for 4 
days before data collection. 24-hour daily water intake and urine output were recorded 
and urine samples were collected under a layer of mineral oil for NE analysis.  
Norepinephrine measurement 
Urinary NE was measured using a Norepinephrine Enzyme-Linked Immunosorbant Assay 
(ELISA) kit (Labor Diagnostika Nord KG, Nordhorn, Germany). A 50-μl urine sample was 
diluted with 950 μl double-distilled H2O to obtain a 20:1 diluted sample, from which 10 μl 
was used for NE measurements based on the instructions provided by the company. 
Duplicate measurements were made for each sample. 24-hour NE excretion was 
calculated from 24-hour urine volume multiplied by NE concentration.  
 50 
Plasma NE was measured after the blood was collected by cardiac puncture following an 
acute terminal experiment. Under 2% isoflurane anesthesia, the heart was exposed via a 
thoracotomy by removing the ventral segment of the 3rd to 6th ribs together with the 
sternum. A 21G needle connected to 1 mL syringe was inserted into the left ventricle. 
Blood was withdrawn slowly and transferred into a 1.5 mL Eppendorf tube containing 10% 
K+ EDTA (10 μl). Blood was centrifuged at 1000×g for 10 min at 4 °C. We were able to 
reliably obtain ∼1 mL blood which resulted in ∼500 μL of plasma, from which 300 μL was 
used to measure the NE concentration using the same ELISA kit as mentioned above. 
Cell culture 
A mouse neural crest-derived cell line Neuro-2A (N2A) cells (CCL-131, American Type 
Culture Collection) were cultured in DMEM media supplemented with 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin. Cells were seeded onto 6-well culture plates 
at a density of 1×105 cells/well for western blot studies. N2A cells were kept in a humidified 
incubator maintained with 5% CO2 at 37°C. 24 hours after cell seeding, differentiation was 
induced by starvation with the FBS reduced to 2% in the DMEM. Each set of cell 
experiments was performed in triplicate.  
Western blot analysis 
Primary antibodies used were Nrf2 (ab62352, R-IgG, 1/1000), Keap1 (sc-33569, R-IgG, 
1/1000), NQO1 (sc-376023, M-IgG, 1/500), HO-1 (sc-10789, R-IgG, 1/200). GAPDH (sc-
32233, M-IgG) or β1-actin (ab-8227, M-IgG) was served as internal loading control.  
For brain tissue analysis the RVLM was punched under a microscope according to 
coordinates taken from Paxinos and Franklin's, the Mouse Brain in Stereotaxic 
Coordinates[130]. For N2A neurons, cells were detached with a cell scraper in 1 mL chilled 
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PBS for each well and were transferred to an Eppendoff tube. After centrifugation at 3000 
rpm for 5 min at 4oC, the supernatant was discarded and the cell pellet was used. Total 
protein was extracted with Radioimmunoprecipitation Assay (RIPA) buffer (PI89901, 
Thermo Fisher Scientific) containing 1% protease inhibitor cocktail (ab201119, Abcam). 
Sample concentrations were measured using a protein assay kit and were adjusted by 4x 
sodium dodecyl sulfate sample buffer to obtain equal concentrations among samples. 
Equal amount of protein samples were loaded into a 8% SDS-PAGE gel (20 μg protein 
per well). The fractionized protein was then subjected to electrophoresis and electrically 
transferred to a polyvinyl difluoride membrane. The membrane was blocked in Phosphate-
buffered saline (PBS) solution containing 5% non-fat milk powder, then was probed with 
primary antibodies to the target protein at 4oC overnight. After incubation with primary 
antibodies, the blot was probed with secondary antibodies at room temperature for 1 hour. 
After thorough washes with PBS containing 1% Tween 20 (PBST), blot bands were 
visualized using an enhanced chemiluminescent system (UVP BioChemi). Bands 
densities were quantified with ImageJ software (NIH). The final data was expressed as 
band densities of the target protein divided by the loading control protein. 
Immunofluorescence and laser confocal microscopy 
Lenti-GFP-Cre viral-induced Nrf2 overexpression or knockout in the RVLM was confirmed 
using immunofluorescence staining. Mice were deeply anesthetized with sodium 
pentobarbital and perfused transcardially with PBS, followed by 4% paraformaldehyde in 
PBS. The entire brainstem was removed, mounted on a specimen stage, and sectioned 
into 40-μm slices in a cryostat. The slices were then washed with PBS three times and 
permeabilized for 30 min at room temperature with a solution containing 0.3% Triton X-
100 dissolved in PBS, followed by blocking with a solution containing 10% normal goat 
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serum and 0.3% Triton X-100 in PBS at room temperature for 2 hours. The slices were 
then incubated with Nrf2 antibody (ab31163 R-IgG), in 10% normal goat serum and 0.3% 
Triton X-100 in PBS at 4 °C overnight. After three washes with PBS, the slices were 
incubated for 2 hours with secondary fluorescent antibody (Goat anti-Rabbit IgG 
secondary antibody, Alexa Fluor 546; Invitrogen, A-11010).  
For oxidative stress immunofluorescence staining assessment, 20-μm brainstem sections 
containing the RVLM were cut on a cryostat. The slices were then permeabilized with 2% 
Triton X-100 at room temperature for 15 minutes. Following blocking with 5% bovine 
serum albumin (BSA), the slices were incubated with 8 hydroxy D guanosine (8-OHdG) 
Antibody (sc-393871, Mouse-IgM, Santa Cruz) overnight at 4°C. Slices were then 
incubated with secondary antibody (ab175472, Donkey-IgG, Alexa Fluor 568; Invitrogen) 
at room temperature for 2 hours.  
Stained sections were mounted with an Aqua-Mount Mounting Medium and visualized 
under a laser confocal microscope (Leica TSC STED). Staining intensities were quantified 
with ImageJ software. 
Statistics  
For cell experiments with one affecting factor, data were analyzed by a one-way ANOVA 
followed by Tukey’s multiple comparisons test. For other data with two affecting factors, a 
two-way ANOVA followed by Tukey’s multiple comparisons test was used to analyze the 
differences among multiple groups. All data were analyzed using Prism 8 (GraphPad 
Software, San Diego, CA) and were expressed as mean ± SE. Differences were 








Chapter IV. Effects of Nrf2 Over-expression in the RVLM on SNA 












As a hallmark of CHF, sympatho-excitation not only exacerbates the failing heart,  but also 
undermines peripheral organ function. Although mainstream therapeutic strategies for this 
syndrome including  β1 adrenergic-blockers, ACEI and ARBs have all been demonstrated 
to ameliorate symptoms and improve disease prognosis, sympathetic outflow is still 
increased. Moreover, side effects such as increased risk of withdrawal syndrome with 
long-term use of β1-blockers or kidney failure with the use of ACEIs are concerned in 
these medications [131]. Therefore, exploring the central mechanisms of sympatho-
excitation appears to be critical to uncover novel therapeutic targets for CHF. 
The RVLM functions as a prime SNA outflow center where pre-sympathetic neurons 
project to the spinal cord. Pathological changes in this area are associated with sympatho-
excitation in CHF. Pre-sympathetic neurons arise from the RVLM and send a 
monosynaptic projection to the IML of the spinal cord [132]. Studies from our laboratory 
showed that reducing oxidative stress in the RVLM either by oral administration of the 3-
Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, simvastatin [133], or by chronic 
exercise training[134], could ameliorate sympatho-excitation in CHF in rabbits.    
Increased oxidative stress in the RVLM contributes to sympatho-excitation[88]. At the 
cellular level, oxygen radicals are primarily produced by mitochondria[135] and NOX [136]. 
These ROS are then scavenged by both enzymatic and non-enzymatic mechanisms[137]. 
In the RVLM of CHF rabbits, we found that the expression and activity of NOX2 subunits 
were upregulated[88] whereas SODs, were downregulated[134], suggesting that the 
increased ROS in the setting of CHF may be a result of enhanced pro-oxidant processes 
and reduced anti-oxidant defenses. We previously demonstrated the upregulation of NOX 
in the RVLM of CHF is attributed to enhanced AngII signaling[88]. However, the 
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mechanisms underlying downregulation of SODs as well as other antioxidant enzymes 
remain to be elucidated.   
As mentioned in the Introduction in Chapter I, the Nrf2/Keap1 complex plays a critical role 
in the redox-sensitive transcriptional regulatory system. Keap1 functions as a sensor of 
ROS and electrophiles, whereas Nrf2 serves as an effector for the coordinated activation 
of cytoprotective genes including a battery of antioxidant enzymes[138]. In the RVLM, this 
system is an important factor in maintaining normal sympathetic tone and BP in conscious 
mice[120]. However, the role of RVLM Nrf2 modulation on SNA in CHF has not been 
elucidated. Therefore, in this Chapter, we tested the hypothesis that overexpression of 
Nrf2 in the RVLM contributes to reduced oxidative stress, upregulation of anti-oxidant 
defenses, resulting in a reduction in SNA in the CHF state.  
Experimental Protocol 
In this experiment, male and female C57BL/6 mice aged between 10 and 12 weeks were 
used. In the initial (first six animals) experiments, we were not able to observe differences 
in infarct size or responses to overexpression of Nrf in males and famales, therefore the 
remainder of the animals were males. In one set of experiments, wild type mice received 
viral vectors encoding for Nrf2 protein or GFP as a viral control; in another set of 
experiments, an alterative strategy of upregulating Nrf2 was employed through Keap1 
deletion via administering Cre lentivirus in Keap1f/f mice. In these Keap1f/f mice, we 
assessed their baseline RSNA as well as plasma NE to further address our hypothesis. 
The general animal study design is shown in Fig 4.1. 
Heart failure model was created by permanent left coronary artery ligation, as described 
above. The sham group underwent a similar procedure without coronary artery ligation. At 
 56 
the fourth week post surgery, cardiac function was evaluated by echocardiography (Vevo 
3100, FUJIFILM VisualSonics). Infarct size was calculated as percentage of LV size using 
ImageJ softwear. One week after echocardiography, mice underwent procedures where 
viral-vectors containing either the Nrf2 gene (20 nl HIV-CamKIIa-eGFP-Nrf2 at 1.3 × 108 
TU/mL)  or Cre recombinase gene (20 nl lentiviral-Cre-GFP at 1 × 108 TU/mL) were 
delivered into RVLM of wild type or Keap1f/f mice, respectively to upregulate Nrf2. Fig 4.2 
illustrates the generation of Keap1 knockout mice. Two weeks after viral injection, the mice 
were implanted with radiotelemetry units and left to recover for three weeks 
postoperatively. BP and HR were then recorded for 48 hours continuously. During 
conscious BP recording, mice were placed in a metabolic cage and a timed urine sample 
was collected. Spontaneous as well as induced baroreflex sensitivity were evaluated as 
per the methods above.  
Under anesthesia, baseline BP, HR, and renal SNA were recorded and arterial baroreflex 
sensitivity was analyzed. Mice were then euthanized by 13% KCl and the maximum RSNA 
was obtained within 1–2 min. Background noise was recorded approximately 15–20 min 
after death. Baseline RSNA was determined as the percent of maximum RSNA activity 
after the background noise was subtracted (Fig 4.3)[139].  
Blood from Keap1f/f  mice was collected following the terminal acute experiment. The urine 
and plasma were used for NE analysis. For each mouse the brain stem was removed and 
the RVLM punched for western blot analysis or immunofluorescence staining.  
All data are expressed as mean ± SE. A two-way repeated measures ANOVA and the 
Student-Newman-Keuls test was used for analyzing the differences among the four 
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Figure 4. 1  Schematic of animal study design 







Figure 4. 2 Generation of Keap1 knockout mice.  
Schematic representation of Keap1 gene targeting vector for tissue-specific 
deletion of Exons 2 and 3 by the insertion of two loxP sites flanking Exons 2 and 
3, respectively. LA, long arm; SA, short arm. 
Kong, Thimmulappa, Craciun, et al.: Enhancing Nrf2 Pathway Inhibits Sepsisfrom [1] 
Figure 4.  2 Generation of Keap1 knockout mice. 
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Tracings of AP (red), HR (green), raw RSNA (blue), and integrated RSNA (black). 
As the final step of the experiment, 13% KCl was given at the break line (black 
arrow), and the maximal RSNA discharge was recorded about one to two minutes 
after KCl was given. Nerve activity was expressed as a percent of maximum after 
subtraction of noise. Top: Sham animal; Bottom: CHF mouse animals.   
 
 
Figure 4. 3 Representative tracing of RSNA recording. 
Figure 4.  3 Representative tracing of RSNA recording. 
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Results 
Evaluation of CHF model 
Four weeks after surgery, the CHF mice exhibited severe heart failure with EF 
approximately 35% as shown in Table 4.1. The weight of infarcted hearts were doubled 
compared to the sham hearts (CHF-GFP 0.25 ± 0.07 vs. Sham-GFP 0.14 ± 0.01, p<0.01). 
The septal and right ventricular free wall were profoundly thickened, whereas the left 
ventricular free wall became paper thin and dilated. Fig 4.4B  shows the M-mode and long 
axis 2D echocardiograms, which confirmed the severity of impaired cardiac functions of 
the infarcted hearts with significantly decreased EF and dp/dtmax. In Table 4.1, grouped 
data of cardiac function in four groups are shown. No significant differences were found 














A. Appearance of the whole heart and infarcts showing enlarged left ventricle (LV) in CHF-
GFP, which seems to be attenuated by Nrf2 overexpression. B. Echocardiograms and 
hemodynamic measurements in Sham and MI hearts treated with RVLM lenti-GFP or 
Nrf2. MI: myocardial infarction. HW: heart weight. EF: ejection fraction.  
  
Figure 4. 4 Assessment of CHF model. 












Table 4.1 Anatomic, hemodynamic, and echocardiographic measurements associated with 
failing hearts. 
 
Sham-GFP Sham-Nrf2 CHF-GFP CHF-Nrf2 
Animal No. 13 13 14 14 
Heart Weight, g 0.14 ± 0.01 0.16 ± 0.02 0.25 ± 0.07∗∗ 0.23 ± 0.06@@ 
Infarct Size, % of LV 0 0 59.9 ± 12.4∗∗ 55.3 ± 15.8@@ 
Ejection Fraction, % 63.6 ± 7.4 65.1 ± 6.9 34.3 ± 5.1∗∗ 37.1 ± 4.3@@ 
Fractional 
Shortening, % 
30.7 ± 6.2 33.5 ± 5.7 13.5 ± 3.1∗∗ 15.3 ± 2.2@@ 
LVEDP, mmHg 2.2 ± 2.4 1.9 ± 2.5 18.8 ± 9.1∗∗ 17.3 ± 8.2@@ 
dp/dt max, mmHg/s 12463 ± 1020 13724 ± 1052 3154 ± 655∗∗ 3298 ± 703@@ 
dp/dt min, - mmHg/s 13101 ± 1112 14166 ± 1281 3540 ± 721∗∗ 3719 ± 772@@ 
Table 4. 1 Anatomic, hemodynamic, and echocardiographic measurements associated with failing hearts. 
**P < 0.01 vs Sham-GFP,  @@P < 0.01 vs Sham-Nrf2. 
 
@@P < 0.01 vs Sham-Nrf2. 
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RVLM Nrf2 over-expression in CHF 
Nrf2 over-expression was obtained through two alternative strategies – Nrf2 gene knock-
in and Keap1 gene knock-out. For the former, Fig 4.5 shows that there is a significantly 
lower level of Nrf2 protein in RVLM in CHF group as compared to the Sham. A similar 
finding was apparent for protein of two Nrf2 target genes, NQO1 and HO-1. Nrf2 gene 
transfer significantly upregulated Nrf2, NQO1, and HO-1 in the RVLM of CHF mice. While 
there was an increase in Nrf2 expression in CHF mice, it did not rise to the level of the 
Sham animals. Nevertheless, it was sufficient to upregulate NQO1 and HO-1 to the Sham 
counterparts. In the RVLM of sham mice, although Nrf2 protein was significantly 
upregulated after Nrf2 gene transfer compared to GFP control, the changes in NQO1 and 







Figure 4. 5 Expression of Nrf2 and two target proteins in the RVLM of Sham and CHF 
mice transfected with GFP or Nrf2 viruses. 
Figure 4.  5 Expression of Nrf2 and two target proteins in the RVLM of Sham and CHF mice transfected with GFP or Nrf2 
viruses. 
Nrf2 gene transfer significantly upregulated Nrf2 (left), NQO1, and HO-1 (right) in the RVLM of 
sham and CHF mice.  GFP: CamKIIa-GFP-virus; Nrf2: CamKIIa-GFP-Nrf2-virus. (*P < 0.05; 
n = 7 in Sham-GFP and Sham-Nrf2 groups; n = 8 in CHF-GFP and CHF-Nrf2 groups). There 





In order to document overexpression of Nrf2 in Keap1f/f mice, we used 
immunofluorescense and western blotting to show protein abundence. Fig 4.6A 
demonstrates upregulation of Nrf2 confirmed by immunofluorescence, which shows that 
neurons that are positive for GFP (green) also express strong Nrf2 immunoreactivity (red 
and in merged image). Western blot for Keap1, Nrf2, NQO1 and HO1 proteins exhibits 
similar results (Fig 4.6B). In both sham and CHF group, delivery of Lenti-GFP-Cre virus to 
Keap1f/f-Cre mouse led to a significantly lower Keap1 and increased Nrf2. NQO1 and HO-





(A) Immunofluorescence images of GFP expression three weeks  after virus administration. 
(B) Western blot data for Keap1, Nrf2, NQO1 and HO1 proteins. These data confirmed 
effective Nrf2 upregulation by Keap1 knock-out. (*P < 0.05 vs GFP groups; # P< 0.05 vs 
Sham-GFP group. n= 6/group.)  
Figure 4. 6 Nrf2, Keap1, NQO1, and HO-1 expression in the RVLM of Keap1f/f mice 
following Lenti-GFP-Cre virus transfection. 
Figure 4.  6 Nrf2, Keap1, NQO1, and HO-1 
expression in the RVLM of Keap1f/f mice 
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Effects of RVLM Nrf2 knock-in on BP, HR, and SNA 
Urinary NE excretion was assessed as an index of sympatho-excitation in order to 
determine if over-expression of Nrf2 in the RVLM reduces sympathetic outflow in heart 
failure. As shown in Fig 4.7A, both NE concentration and excretion were significantly 
elevated in the CHF-GFP group compared to the Sham-GFP group. Nrf2 over-expression 
in the CHF group significantly reduced total urinary NE excretion, suggesting that 
upregulating RVLM Nrf2 suppresses sympathetic outflow in CHF.  
For arterial sBRS, data in Fig 4.7B demonstrates that in CHF, both up-sequence gain 
(1.23 ± 0.20 versus 3.71 ± 0.32 ms/mm Hg, *P < 0.05, n = 8 and 7) and down-sequence 
gain (0.90 ± 0.21 versus 2.87 ± 0.19 ms/mm Hg, *P < 0.05; n = 8 and 7) were significantly 
decreased, whereas Nrf2 over-expression restored the BRS (up-sequence gain: 
2.45 ± 0.31 ms/mm Hg, down-sequence gain: 2.30 ± 0.32 ms/mm Hg; †P < 0.05 vs CHF-
GFP, n = 8 for each group).  
We also evaluated the induced BRS by measuring hemodynamic responses to i.p. 
injection of phenylephrine. Fig 4.7C shows that there were no differences in BP changes 
among these four groups (upper panel), however, the decline in HR (lower panel) was 
significantly reduced in the CHF state, reflecting a diminished BRS. Again, an improved 
BRS was seen in the RVLM Nrf2 over-expression group of CHF mice. Together, these 
data indicate that RVLM Nrf2 over-expression improves both spontaneous- and induced- 





Figure 4. 7 Sympathetic outflow and cardiovascular regulation in conscious mice. 
n.s 
(A) Urinary NE; (B) Spontaneous Baroreflex Sensitivity; (C) Induced Baroreflex 
Sensitivity. Left panel in (C) is a representative tracing of MAP and HR of one mouse after 
ip PE; Right panel in (C) is mean data showing the percent decline of HR following PE 
induced increase in BP. (*P < 0.05 and **P < 0.01 vs Sham-GFP; †P < 0.05 vs CHF-GFP. 






Figure 4.  7 Sympathetic outflow and 
cardiovascular regulation in conscious mice. 
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Effects of Nrf2 overexpression in RVLM on RSNA and baroreflex in the anesthetized state 
Direct measurement of RSNA is difficult to directly record in conscious mice. Therefore, 
we adopted methods of SNA recording in the anesthesia state. Figure 4.8A shows original 
tracings of basal RSNA as well as RSNA responses to PE-induced HTN (baroreflex). 
These recordings demonstrate an increased baseline neural discharge and a blunted 
sympatho-inhibitory response during HTN in CHF-GFP treated as compared to Sham-
GFP treated mice. Mice treated with Nrf2 virus exhibited a restored sympatho-inhibitory 
response in CHF. Figure 4.8B displays the mean data for basal RSNA frequency, 
integrated nerve activity, and normalized nerve activity. All three parameters were found 
to be higher in the CHF-GFP treated group compared to the Sham-GFP group. In CHF 
mice, these parameters were reduced in the Nrf2 overexpression group. The composite 
baroreflex curves/gains (Figure 4.8C, top) and four parameters of reflex sensitivity (bottom) 
are shown. The maximal gain, average slope and range of RSNA response were 
significantly decreased, whereas the BP50 and minimum RSNA were significantly higher 
in the CHF-GFP group compared with the Sham-GFP group. Nrf2 over-expression in CHF 












(A) Original recording; (B) Analysis of basal sympathetic nerve activity; (C) Baroreflex curves 
and curve parameters. PE: Phenylephrine. *P < 0.05 and **P < 0.01 vs Sham-GFP; †P < 0.05 
vs CHF-GFP. n = 6. 
 







Figure 4.  8 Renal sympathetic nerve activity and 
baroreflex sensitivity under 
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Effects of Keap1 knock-out in RVLM on RSNA 
Since the RVLM Keap1 knock-out showed a significant increase in Nrf2, NQO-1, and HO-
1 in CHF mice, we determined their basal RSNA and plasma NE to evaluate these 
physiological effects. As shown in Fig 4.9A, RSNA in CHF-Keap1f/f-GFP mice was 
markedly higher as compared to Sham-Keap1f/f-GFP group. Similar to the results seen for 
direct Nrf2 virus knock-in animals, indirect upregulation of Nrf2 in the CHF-Keap1f/f-Cre 
mice, the basal RSNA in CHF was attenuated compared to CHF-Keap1f/f-GFP group. 
Similar to direct Nrf2 knock-in, Keap1 knock-out did not alter baseline RSNA in sham 
animals. Similar patterns were observed for plasma NE concentration between each group 
(Fig 4.9B). Together with the Nrf2 knock-in data above, these results strongly indicate that 
manipulating Nrf2 has a direct impact on sympatho-excitation in the CHF state.  












(A). RSNA recording (upper) and mean data (lower) show a higher basal RSNA in CHF-
Keap1f/f-GFP mice as compared with Sham-Keap1f/f-GFP; the increased basal RSNA was 
ameliorated in CHF-Keap1f/f-Cre mice. (B). The increased plasma NE concentration in CHF-
Keap1f/f-GFP mice was restored after Keap1f/f-Cre treatment.  *P<0.05 vs GFP groups; 








Figure 4. 9 Basal RSNA and plasma NE concentration in CHF-Keap1f/f-GFP mice. 
n.s 
n.s 
Figure 4.  9 Basal RSNA and plasma NE 
concentration in CHF-Keap1f/f-GFP mice. 
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Discussion 
CHF are characterized by increased SNA. In early stage CHF, sympatho-excitation is an 
important compensatory mechanism in maintaining hemodynamic stability in response to 
impaired cardiac function. However, long-lasting sympatho-excitation eventually leads to 
a vicious cycle and contributes to the progression of HF. Current therapeutic strategies for 
CHF including ACEIs and β-adrenergic antagonists mainly focus on the peripheral 
sympathetic regulation, and their potential adverse effects may contribute to the worsening 
of this condition. For example, β adrergic-blockade protects myocytes but leaves the α-
receptor vulnerable to sympathetic stimulation and may result in vasoconstriction and 
reduced tissue perfusion. Since the augmented sympathetic tone in the CHF state 
originates centrally, this study aimed to elucidate one potential mechanism of sympatho-
excitation in the CNS in CHF to provide further evidence for a potential novel central 
therapy, perhaps by targeting central delivery via nanoparticles or exosomes. 
In this study, we adopted the widely used method of left anterior descending (LAD) 
coronary artery ligation to establish CHF model. While there are other methods for small 
animal HF models such as transverse aortic constriction (TAC), LAD ligation mimics the 
most severe cause of HF in humans (coronary thrombosis) resulting in MI. This model has 
been reliably shown to result in neurohumoral activation similar to that is seen in humans 
with CHF. In addition, the established correlation between infarct size and LV function 
made LAD ligation model more feasible in quality control [140, 141]. The TAC model on 
the other hand, results in pressure overload, cardiac hypertrophy and remodeling, but 
does not result in CHF until very late in the disease (many months)[142]. 
In the LAD ligation induced CHF model, we found that Nrf2 protein and two of its targets, 
NQO1 and HO-1, in the RVLM of CHF mice were significantly downregulated compared 
 74 
to the Sham group. Upregulating Nrf2 by introducing an HIV-CamKIIa-eGFP-Nrf2 virus 
into the RVLM of C57BL/6, or by introducing lentiviral-Cre-GFP in Keap1f/f mice 
significantly restored the decreased Nrf2, NQO1, and HO-1 in CHF mice. Upregulation of 
Nrf2 also improved arterial baroreflex function, lowered plasma and urinary excretion of 
NE, and reduced RSNA. These data strongly suggest that an impaired antioxidant defense 
at least partially contributes to sympatho-excitation in CHF, and upregulation of Nrf2 can 
ameliorate the increased SNA. Therefore, enhancement of antioxidant mechanisms in the 
RVLM may be a potential strategy in treating or preventing diseases like CHF and HTN. 
The relative lack of statistically significant restoration of cardiac function (EF, FS) in the 
CHF mice after Nrf2 overexpression was not surprising due to the severe and large MI 
created in this model. In general, mouse MI models result in infarct sizes too large to 
reverse cardiac dysfunction following most interventions. This is an intrinsic limilation of 
the mouse MI model. A reduction in RSNA in this model may benefit the peripheral 
vasculature more than the myocardium. To minimize this limitation, one needs to evaluate 
modulation of Nrf2 in other models of CHF.  
The lack of complete normalization of Nrf2 protein following Keap1 knockdown in CHF 
animals is not clear. However, this is not surprising given the lower level of Nrf2 
expression seen in the CHF group and the likelihood that there are other factors that 
regulate NQO1 and HO-1 in addition to Nrf2 (e.g. proteosomal degradation).  
In a previous study we showed that selective deletion of Nrf2 and the consequent 
enhancement of oxidative stress in the RVLM lead to sympatho-excitation and HTN [120]. 
This suggests that redox homeostasis is essential for normal function of sympathetic 
networks. It has been shown that enhanced oxidative stress and reduced antioxidant 
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defense in the RVLM are responsible for sympatho-excitation in both CHF [143] and HTN 
[144]. While we did not exam all antioxidant proteins, NQO1 and HO-1 were markedly 
downregulated in the RVLM in CHF. The underlying mechanisms for this downregulation 
are not clear. In this study, we found that Nrf2 expression in the RVLM of CHF mice was 
significantly lower than that in Sham mice, suggesting that the dysfunctional transcription 
of antioxidant enzyme genes may be responsible for the impaired antioxidant defense. 
Using two methods we showed that upregulating RVLM Nrf2 through gene transfer 
restores impaired baroreflex sensitivity which is characterized by sympatho-excitation. 
These findings are also consistent with studies from other groups where a downregulation 
of Nrf2 protein in the PVN in the SHR was observed [145]. In these studies, investigators 
administered a selective Nrf2 activator, tert-butylhydroquinone (tBHQ), and found that 
both BP and SNA were significantly reduced.  
The cellular mechanisms by which over-expression of Nrf2 alters RVLM neuronal activity 
in mice with CHF is still unknown. The pre-sympathetic neurons in the RVLM are 
categorized as C1 or non-C1 groups based on the expression of phenylethanolamine N-
methyltransferase (PNMT), and both groups utilize glutamate as the primary excitatory 
neurotransmitter [146] and can be targeted by a CAMKIIa vector. In a recent study it was 
reported that in mice, optogenetic activation of C1 cells alone results in a decrease in BP, 
but when C1 and non-C1 cells were stimulated simultaneously, BP was markedly 
increased [147], suggesting different functions of C1 and non-C1 cells in the RVLM. In this 
study because of the use of HIV-CamKIIa-GFP-Nrf2 vector, we were not able to 
distinguish between these two cell types. We assume that upregulation of Nrf2 in all 
glutamatergic neurons in the RVLM contributes to the amelioration of sympathetic 
dysfunction. The findings from the Keap1f/f mouse model indicate that overexpressing Nrf2 
in a more widespread manner in the RVLM, including neurons and non-neuronal cells, 
 76 
also contributes to the suppression of SNA in CHF, suggesting a global oxidative stress 
in the RVLM. Increased ROS can remarkably impact neurons and glial cells by direct 
oxidation of lipids, proteins, and DNA as well as the induction of mitochondrial injury [148]. 
By oxidative modification of potassium channels [149], the excitability of neuronal cells is 
increased while pro-inflammatory cytokines are released from activated glial cells [150]. 
In addition, Nrf2 also plays a critical anti-inflammatory role in the cross-talk between Nrf2 
and NF-κB, through competing for binding to CBP (CREB-binding protein) thus depriving 
its interaction with NF-κB thereby decreasing pro-inflammatory activity[118]. All these 
mechanisms may underly the dysfunction in the RVLM in the CHF state. 
It is possible there may have been sex differences in the responses to overexpression of 
Nrf2 and sympathoinhibition as human studies have shown these gender differences[151]. 
However, our initial studies did not show major differences in the effect of RVLM Nrf2 on 
SNA. In addition, our Keap1f/f mouse line produced slightly more males than females, 
therefore there were more males in this study. For a more thourough exploration of sex 
differences, future studies need to be done with more female animals included and a 
separate analysis done. 
In summary, data from this study suggest that enhanced oxidative stress in the RVLM in 
CHF may be attributed to reduced transcriptional regulation of antioxidant genes, thus 
resulting in sympathetic overactivity. Furthermore, upregulating antioxidant enzyme 
expression through the Nrf2-Keap1 pathway in the RVLM may be a potential new 
therapeutic strategy to improve autonomic regulation in CHF. While we investigated the 
RVLM, our data does not rule out important contributions from other autonomic areas in 








Chapter V. Effects of ACE2 over-expression in the Brain on 











HTN is one of the most common causes of morbidity and mortality, worldwide. Essential 
HTN is characterized, in part, by activation of the RAAS and SNA [152]. There is a 
consensus that much of what is called “essential” HTN has a neurogenic component [153]. 
The circulating and central RAAS alter autonomic function and it is well accepted that 
central AngII increases AP by activating SNA and vasopressin secretion indicating the 
primacy of central alterations in the response to AngII [154]. The areas of the CNS that 
regulate cardiovascular function and sympathetic function are, to a large degree, centered 
around the RVLM and integrative areas of the brain stem such as the hypothalamus, the 
organum vasculosum of the lamina terminalis and the NTS, among others. Alterations in 
the function of these centers have been shown to play a critical role in CVD [155]. Through 
activation of AT1R, AngII activates several downstream signals to elicit enhanced 
sympathetic activation and pressor effects [156].  
The ACE homolog ACE2 is a carboxy peptidase that cleaves the terminal phenylalanine 
from AngII to form Ang1-7. This metabolite is an important component of the RAS system, 
the so-called “good arm of the RAAS” [65, 157]. In previous work from this laboratory we 
have shown that rabbits with CHF exhibit increased ACE and decreased ACE2 in several 
central nuclei including the RVLM, the PVN and the NTS [101]. We also demonstrated 
that SNA was significantly reduced in CHF mice that overexpress ACE2 in the brain[68]. 
Similarly, in HTN, Sriramula et al. showed attenuation of the pressor response to 
peripheral infusion of AngII in mice that overexpress ACE2 in the brain. The same group 
also showed that peripheral AngII infusion increased oxidative stress in the PVN and 
RVLM significantly more in ACE2 knockout mice compared to their non-transgenic 
littermates [75]. By over-expression of ACE2 in the RVLM, Yamazato et al. showed a 
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significant decrease in BP in the SHR rats [158]. However, the exact mechanisms by which 
central ACE2 reduces sympathetic outflow in HTN are not quite clear. 
Sympatho-excitation is increased by central AngII activity, especially in the autonomic 
regulating areas mentioned above. Thus, it is rational to speculate that the sympatho-
inhibitory effects of ACE2 is the result of decreased AngII due to the conversion to Ang 1-
7. However, some studies [159] showed that in global ACE2 knockout (KO) mice, while 
their systolic BP was comparable to wild type mice, vasodilator function was significantly 
impaired. ACE2 deficiency - induced vascular dysfunction was improved by Tempol, a 
superoxide dismutase-mimetic. More importantly, AngII levels were not significantly 
different between adult ACE2 KO and WT mice. These studies suggest that ACE2 plays 
an important role in regulation of oxidative stress through an AngII independent pathway. 
Ang1-7 is the product of AngII being converted by ACE2 and has been show to possess 
vasodilator activity as an opposing effect to that of AngII [160]. By binding to the MasR, 
Ang1-7 negatively modulates AngII/AT1R–activated c-Src and its downstream targets 
ERK1/2 and NOX in endothelial cells[161]. Diz et al. [162] and others have provided 
evidence that Ang 1-7 enhances baroreflex sensitivity and exerts sympatho-inhibitory 
effects. Gironacci et al. showed that Ang 1-7 decreased NE release from the 
hypothalamus of SHR[72]. Therefore, it is plausible to presume that the anti-sympathetic 
effect of ACE2 may be through increased Ang1-7 converted from AngII. However, the 
central effect of Ang1-7 still remains controversial in terms of SNA control. Potts et al. 
showed that Ang 1-7 exhibits a sympatho-excitatory effect when given into the RVLM in 
anesthetized rabbits [69]. Silva et al. also demonstrated that injection of the MasR 
antagonist, A-779 in the PVN decreases RSNA in anesthetized rats, indicating a possible 
sympatho-excitatory quality of Ang1-7 [71]. Based on these studies, there may be another 
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mechanism that is not directly related to either AngII or Ang1-7 that mediates the anti-
sympathetic effects of ACE2.    
In order to assess the role and potential mechanism of central ACE2 in regulating BP and 
sympathetic overactivity, we evaluated responses of ACE2 over-expression in the mouse 
brain to central AngII- induced HTN.  
Experimental Protocol 
This experiment was performed on 3-month-old male SynhACE2+/+ transgenic mice and 
their non-transgenic littermates on the C57BL6 background. The experimental design is 
shown in Fig 5.1 below.  
All mice were instrumented with a radio telemetry unit (PA-C10; Data Sciences 
International Inc., Minneapolis, MN) with the catheter inserted into the left common carotid 
artery as described in Chapter III. Animals were allowed to recover for 1 week before 
hemodynamic recording. MAP and HR were measured 2 hours daily from noon to 2:00 
PM. A 24-hour recording was attained each week usually on a Saturday or Sunday. 
Following 3 days of baseline recording, a cannula connected to a 14-day osmotic 
minipump (Model 1002, Alzet, Inc. Cupertino, CA) was implanted into the right lateral 
ventricle at a pumping rate of 0.25 ul/hour, to create a hypertensive model by chronic ICV 
infusion of AngII. The control group received aCSF. In order to avoid acute postoperative 
stress induced high BP, mice of all groups were equipped with minipumps filled with only 
aCSF for 1 week before switching to minipumps filled with different drugs. The protocol 
timeline is demonstrated below. After each group received the assigned treatment with 
AngII (100 ng/kg/min)[163], Ang1-7 (200 ng/kg/min) or A779 (400 ng/kg/min)[164]. These 
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doses are based upon previous studies and on the fact that AngII at this dose does not 
evoke an increase in BP when given peripherally[163]. 
During hemodynamic recording, mice were placed in a metabolic cage. After a 3-day 
adaptation, 24-hour urine samples were collected daily and saved for NE analysis. Mice 
were sacrificed 14 days after ICV infusion of different treatments. Brains were removed 
after euthanasia, some brainstem RVLM punches were used for western blot analysis, 
some tissue was used for immunofluorescence staining.  
Results were analyzed by 2- way ANOVA for repeated measures followed by Bonferroni 
correction or Tukey’s test for multiple comparisons. All data are expressed as mean ± SE. 
Statistical analysis were performed using Prism8 (GraphPad Software, Inc. San Diego, 











Post-Ang II or Ang II ± Ang1-7/A779 
data collection
Water and urine recording




Figure 5. 1 Experimental design 
Figure 5.  1 Experimental design 
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Results  
Central SynhACE2 attenuates ICV AngII - induced HTN  
To evaluate the effect of SynhACE2 over-expression on hemodynamic changes induced 
by central AngII, we assessed MAP and HR over 2 weeks of ICV AngII administration in 
both SynhACE2+/+ mice and their control littermates as described above. As shown in Fig 
5.2A, in non-transgenic (SynhACE2-/-) animals, chronic ICV infusion of AngII significantly 
increased MAP (AngII [average of post-ICV day 1-9] 126.4±2.0 mmHg vs baseline 
[average of 3-day recordings] 92.7±1.5 mmHg n=7, P<0.05) as well as compared to aCSF 
infusion controls (AngII [average of post-ICV day 1-9] 126.4±2.0 mmHg n=7, vs. aCSF 
[average of post-ICV day 1-9]  96.1±0.9 mmHg, n=5 P<0.05). The aCSF treated group did 
not show altered MAP from baseline level after treatment. ACE2 over-expression 
attenuated AngII-induced HTN to a level that was comparable to the vehicle treated 
SynhACE2-/- group (MAP [average of post-ICV day 1-9] of AngII/synACE2+/+: 101.1±2.1 
mmHg, n=5).  There were no effects on HR in any of the treatment (Fig 5.2B).  
To determine if the inhibition of the hypertensive effect of AngII in SynhACE2+/+ animals is 
mediated through an enhancement of the Ang1-7/MasR pathway, we co-administered 
MasR blocker, A779 with AngII to SynhACE2+/+ mice. As is shown in Fig 5.2A, the 
attenuated high BP due to AngII was not prevented by co-infusion of A779 in SynhACE2+/+ 
animals (SynhACE2+/+/AngII/A779 vs SynhACE2+/+/AngII: 97.9±10.6 vs 98.7±14.2mmHg, 
p>0.05). If the conversion of AngII to Ang1-7 by overexpression ACE2 was the mediator 
of the inhibition of the AngII pressor response, we would assume that Ang1-7 itself would 
show a similar benefit. Therefore, we co-administered Ang1-7 with AngII to SynhACE2-/- 
mice failed to blunt the pressor response induced by AngII. These data suggest that MasR 
activation may not be the primary mechanism of ACE2 attenuating central AngII induced 
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HTN. We interpret the findings as indicating that the primary mechanism by which ACE2 
overexpression reduces the pressor response to central AngII is through degradation of 
AngII, rather than increased Ang1-7. However, we do not have peptide measurements to 
confirm this.  
The 24-hour hemodynamic data prior to and after AngII treatment are summarized in 
Table 5.1 and are separated by day and night averages. A circadian variability was clearly 
visible in both aCSF and AngII infusion groups. Fig 5.3  summarizes the day and night 
data of MAP and HR before and after ICV infusion. Chronic ICV AngII evoked a pressor 
response in both the day and night compared to aCSF in SynhACE2-/- mice. However, this 
change was markedly inhibited in SynhACE2+/+ mice. HR also tended to rise with ICV 









A. Chronic ICV AngII infusion induced a progressively increased mean arterial BP in the 
SynhACE2-/- mice, which was completely blunted in the SynhACE2+/+ mice. Chronic ICV 
co-administration of AngII and Ang 1–7 in SynhACE2-/- mice did not attenuate the pressor 
response, nor did co-administration of AngII and Mas receptor blocker A779 in 
SynhACE2+/+ mice reverse the anti-hypertensive effect. Baseline BP was not altered by 
ACE2 over-expression. B. HR was not affected by ICV-AngII in any of the genotypes. (n=5-
7; #p < 0.01 vs. SynhACE2-/- /aCSF post-ICV; #p < 0.05 vs. SynhACE2-/- /AngII post-ICV). 
 
A B. 
Figure 5. 2 Central SynhACE2 overexpression attenuates ICV-AngII induced BP 
increase. 












Table 5.1 Baseline and post-infusion day-night hemodynamics 
  synhACE2-/- SynhACE2+/+ 
  aCSF AngII aCSF AngII 
  Day Night Day Night Day Night Day Night 
Baseline 
MAP(mmHg) 95.1±4.2 106.6±11.8* 102.1±3.8 112.8±6.9* 91.7±4.2 103.5±2.7* 97.8±3.5 112.0± 7.1* 
HR(BPM) 525.2±99.7 510.1±156.1 474.2±140.4 479.3±159.5 559.1±170.9 578.1±164.2 533.6±101.2 583.9±124.1 
Post-icv 
MAP(mmHg) 93.4±6.8 108.2±11.8* 120.7±9.6** 127.7±12.1** 98.5±6.9 111.1±8.6 100.9±21.7# 115.3±28.1*# 
HR(BPM) 430.3±142.3 490.6±154.7 546.7±37.8 595.4±70.8 464.2±123.3 532.5±188.6 500.3±79.7 573.9±131.6 
Each value is the 12 hour average of grouped data based on 24-hour BP and HR recordings. (n=5-
7, *p<0.05 night time vs day time-MAP; **p<0.01 vs SynhACE2- Baseline MAP; #p<0.05 vs 
SynhACE2- Post AngII-infusion MAP)  
 
Each number is the averaged value of grouped data based on 24-hour BP recordings. (n=5-7, 
*p<0.05 night time vs day time-MAP; **p<0.01 vs SynhACE2- Baseline MAP; #p<0.05 vs 











24 hour MAP in four groups before (A) and after (B) ICV infusion of AngII or aCSF. No 
difference were shown between groups in the baseline blood pressure. AngII infusion 
significantly increased MAP compared to aCSF group. ACE2 overexpression completely 
blocked the increase of MAP in response to ICV-AngII(n=5, *p<0.05). SynhACE2+/+ /aCSF 
group did not show significant change in MAP compared to SynhACE2-/-/ aCSF control.  
 
  

















Figure 5. 3 Day-night circadian MAP before and after ICV infusion 
Figure 5.  3 Day-night circadian MAP 
before and after ICV infusion 
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SynhACE2 attenuates central AngII induced polydipsia  
AngII is well known for its ability to trigger thirst and fluid intake [165]. To assess the effect 
of ACE2 over-expression on central AngII - induced drinking response, we recorded daily 
water intake and urine output for each group of animals. Baseline daily water intake and 
urine generation showed no difference between animals of all genotypes. With central 
AngII treatment, the effect on drinking behavior is shown in Fig 5.4. In SynhACE2-/- animals, 
the peak values for daily water consumption markedly increased from a baseline of 
5.6±0.2ml to 25.9±0.6 ml (n=5, p<0.05), with a significant increase in 24-hour urine 
excretion concomitantly from 1.6±0.3 to 13.9±1.5 ml (n=5, p<0.05). This enhancement of 
fluid intake started gradually after AngII infusion and was sustained during the infusion. In 
SynhACE2+/+ mice however, the drinking and urine volumes in response to ICV AngII were 
attenuated (ΔH2O volume=10.5±2.1 ml, Δ Urine volume=6.9±1.7 ml n=5, p<0.05) 
compared to their non-transgenic littermates. There were no differences between 











A. Chronic AngII infusion produced an overall increased water intake during the 2-week 
infusion period, the response was reversed in SynhACE2+/+ mice (n=4-5; *p < 0.05). B. The 
increased urine output due to central AngII was blunted in SynhACE2+/+ mice (*p < 0.05 vs. 
aCSF; #p < 0.05 vs. SynhACE2-/-; n=4-5). 
A. B. 
Figure 5. 4 ACE2 over-expression attenuates the enhancement of central AngII 
induced polydipsia and polyuria. 
Figure 5.  4 ACE2 over-expression attenuates the 
enhancement of central AngII 
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SynhACE2 attenuates central AngII-induced sympathetic overactivity 
To determine if the anti-hypertensive ability of SynhACE2+/+ mice in response to central 
AngII is due to a reduction in SNA, we measured 24-hour urinary NE excretion and 
evaluated HRV as indirect indicators of SNA. HRV was evaluated in the perspectives of 
both the time-domain, as reflected by the standard deviation of HR (SDRR), and the 
frequency-domain, as reflected by low-frequency (LF) to high-frequency (HF) power 
spectral ratio using pulsatile BP data.  
Fig 5.5A shows changes of 24-hour NE excretion in each group. While baseline 24-hour 
NE excretion were similar between all animals, ICV AngII infusion in the SynhACE2- group 
markedly increased NE excretion compared to their baseline level, as well as to 
SynhACE2+/+ or aCSF mice. This enhancement of NE excretion due to AngII was 
prevented in animals with ACE2 over-expression. However, NE excretion was not altered 
in SynhACE2+/+ mice after aCSF infusion compared to baseline. Fig 5.5B and 5.5C show 
a clear decrease in SDRR as well as an increase in LF/HF in the AngII treated SynhACE2-
/- group, indicating cardiac autonomic responses was skewed to an increased sympathetic 
activation. These changes were also normalized in mice overexpressing central ACE2. 
Taken together, these data suggest that selective over-expression of ACE2 in the brain 
can prevent the AngII induced disturbance in autonomic nervous activity reflected by 







Figure 5. 5  SynhACE2+/+ attenuates central AngII- induced sympathetic hyperactivity. 
A. 24h NE excretion was reduced in SynhACE2+/+ mice. (n=4; *p < 0.01 compared to synhACE2-
/- /aCSF post-ICV; #p < 0.05 compared to SynhACE2-/- /AngII post-ICV.)  SDRR (B) and LF/HF 
(C) during baseline and post-infusion period showed ACE2 overexpression improved AngII 
induced HR variability impairement. (n=3-4; *p < 0.05 compared to SynhACE2-/-  AngII-baseline; 
#p < 0.05 compared to SynhACE2-/-  /AngII-Post-ICV) 
Figure 5.  5 SynhACE2+/+ attenuates central AngII- induced sympathetic hyperactivity. 
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SynhACE2 attenuates central AngII-induced oxidative stress 
To determine if over-expression of ACE2 could prevent central AngII mediated ROS 
production, we measured oxidative stress using 8-hydroxydeoxyguanosine (8-OHdG) 
immunostaining of brainstem slices containing RVLM areas. ROS oxidize lipids, proteins 
and nucleic acids and cause cellular lesions. Since DNA is prevalent in both nuclei and 
mitochondria, evaluating DNA damage is widely used to assess cellular oxidative stress. 
8-OHdG, is an oxidized nucleoside of DNA frequently used for such assessment. As 
shown in Fig 5.6, central AngII infusion markedly increased RVLM DNA oxidation in 
SynhACE2- animals. The enhanced immunostaining intensity was reduced in 
SynhACE2+/+ mice treated with ICV AngII, to the extent comparable to that of the aCSF 
group. ACE2 over-expression itself did not seem to alter redox state in aCSF treated 
animals. Taken together, these data confirmed that central SynhACE2 over-expression 
















Representative 8-OHdG immunofluorescence staining in the RVLM (A) and quantified data 
(B) showed that ICV AngII infusion significantly increased DNA oxidation in the RVLM area 
of SynhACE2-/- mice, but not in SynhACE2+/+ group. ACE2 over-expression did not change 
ROS production during aCSF treatment. (n=4, *p<0.05 vs. SynhACE2-/AngII; #p<0.05 vs. 
SynhACE2-/- /aCSF). 
 
Figure 5. 6  SynhACE2+/+ mice exhibit anti-oxidative stress property in response to 
central AngII. 
Figure 5.  6 SynhACE2+/+ mice exhibit anti-oxidative stress property in 
response to central AngII. 
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Discussion 
The current study provides evidence that ACE2 upregulation in the brain abolishes the 
central pressor effect of AngII in conscious mice. Because this effect has been shown to 
be mediated by a reduction in oxidant stress elicited by AngII [75] we hypothesized ACE2 
overexpression in the brain would decrease the sympathetic and ROS responses to 
central AngII. 
It has been shown that increased levels of circulating AngII are present in patients with 
severe primary HTN [166]. In addition to the vasoconstrictor effects of circulating AngII, 
HTN can be evoked by the direct effects of AngII on brainstem neurons either through 
regions lacking a brain blood barrier (BBB), or through impaired BBB due to chronic HTN 
[167, 168]. Although studies have shown evidence that peripheral AngII can access 
neurons in the brainstem [169], increased AngII originating  from the CNS also contributes 
to central RAAS over-activation [170]. Therefore, chronic ICV administration of AngII is a 
plausible approach to create a model for primary HTN.  
As indicated above, it is believed that the mechanism of central AngII induced HTN is 
through generation of ROS which consequently excites sympathetic neurons resulting in 
increased BP. This concept was confirmed by our data (Fig 5.5 and Fig 5.6). It is 
reasonable to speculate that targeting either AngII or ROS centrally would attenuate 
primary HTN. In this study using SynhACE2+/+ mice, we were able to target central AngII 
and ROS to confirm the mechanism for the anti-hypertensive property of central ACE2 
over-expression. 
Although it has been well accepted that the Ang1-7/MasR axis possesses a variety of 
protective effects on cardiovascular function, it is still not clear if Ang1-7 is the key mediator 
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for the anti-pressor effects of ACE2 in response to AngII administration. Due to the 
complexity of central nuclei and inter-nuclear communication, there may exist many 
variables that make the same effector exert opposite influences. Fontes et al. showed that 
microinjection of Ang 1-7 directly into rat RVLM increased MAP at a dose of 25 pmol [70]. 
Feng et al. showed that chronical subcutaneous (s.c.) infusion of A779 (600 ng/kg/min) 
reversed the anti-pressor effect of central ACE2 in response to peripherally administered 
AngII (600 ng/kg/min, s.c.) [122]. Based on these findings it is hard to reach to a firm 
conclusion in terms of the effect of Ang 1-7 since the results seem to involve several 
factors including dose, administration route, target location, etc. Feng et al. showed that 
SFO selective over-expression of ACE2 attenuates the pressor effect of AngII (ICV bolus), 
which was not reversed by the MasR antagonist, A779 [76]. Wysocki et al. [171] showed 
that subcutaneous infusion of human recombinant ACE2 prevented the hypertensive 
effect of AngII (1000 ng/kg per minute, s.c.) and this effect was not blocked by A779 (100 
ng/kg/min, s.c.) infusion. In Wistar rats, Campagnole-Santos et al. observed that ICV Ang 
1-7 failed to attenuate central AngII induced BP increase, but improved baroreflex 
sensitivity impairment [172]. Our data are largely consistent with these findings, which 
seem to indicate there exists discrepancies between central and peripheral, or between 
different nuclei with regard to responses to RAAS component interactions.  
In the current study, inhibition of the pressor response to central AngII in SynhACE2+/+ 
mice was not altered by infusion of MasR antagonist A779. We speculate that AngII 
degradation may constitute the major mechanism by which central ACE2 over-expression 
inhibits this response. However, given some evidence that ACE2 can act as an antioxidant 
[159], other factors such as anti-oxidant defense systems may play an intermediate role.   
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In this study we used only male mice instead of both genders. Numerous studies have 
demonstrated the differences in BP between age-matched male and female human 
beings[173]. In many animal studies, sex differences in local RAAS activities have been 
indentified in several peripheral organs and in different compenents of RAAS[174]. 
Although direct evidence of the existence of sexual dimorphism in central ACE2 
expression is relatively lacking, and there does exist BP differences to peripheral AngII 
infusion between genders [174, 175], our initial studies with both genders did not show 
major difference in the responses to centrally administered AngII. However, in order to 
apply the conclusions of this study to both genders, further studies need to be done.  
In summary, the current study shows that brain selective over-expression of ACE2 
profoundly abolished the pressor response to central administration of AngII. The MasR 
agonist Ang 1-7 and blocker A779 had no effects on BP or drinking responses following 
central AngII infusion, skewing the underlying mechanism towards an effect of ACE2 on 
AngII-AT1R signaling. The data suggest that a reduction in central oxidative stress  may 
























 Nrf2 plays an important role in the development of primary HTN, based on both direct and 
indirect evidence [176-178]. In a previous study we demonstrated that selective deletion 
of Nrf2 in the RVLM in normal mice led to a downregulation of antioxidant enzymes and 
elevated ROS, resulting in increased SNA and BP [120]. This suggests that central  Nrf2 
contributes to BP BP regulation via modulation of oxidative stress and SNA. Senanayake 
et al. found that administration of a dietary phase 2 protein inducer, sulforaphane (SFN), 
lowered BP in spontaneously hypertensive stroke-prone (SHRSP) rats to a level 
comparable to normal Sprague Dawley rats [179]. Noyan-Ashraf et al.[180] demonstrated 
that female SHRSP on a diet high in glucoraphanin exhibited in lower BP due to its 
metabolite, SFN. Although Nrf2 was not directly messured in their study, the observed 
effects were potentially due to the upregulation of Nrf2 expression and function induced 
by SFN. As a master regulator of a variety of antioxidant enzymes, Nrf2 may mediate an 
important mechanism in the pathogenesis of primary HTN. However, whether Nrf2 
deficiency is a cause of the development of HTN, or it is an adaptive mechanism as a 
result of HTN is not clear.  
The potential interaction between central Nrf2 and the RAAS, on the other hand, is an 
important question to be elucidated. A direct relation between Nrf2 and the RAAS has 
been indicated in several studies. Chang et al. [181] showed that overexpression of 
angiotensinogen in mouse renal proximal tubular cells downregulates Nrf2 signaling, thus 
increasing BP. Zhao et al. [182] found that Nrf2 deficiency upregulates intrarenal ACE2 
and Ang1-7 MasR expression and attenuates HTN. Kang et al. showed that AngII 
suppresses Nrf2 signaling in the renal epithelial cells in a model of renal fibrosis [183]. The 
studies above suggest that Nrf2 and the RAAS may interact in the regulation of SNA and 
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BP. However, most of these studies were limited in the kidney. In the CNS, especially in 
the background of cardiovascular disease like HTN, the interaction between Nrf2 and the 
RAAS is yet to be defined.  
Based on the evidence in the above chapters that both Nrf2 and ACE2 overexpression in 
the brain attenuates oxidative stress, inhibits sympathoexcitation and prevents BP 
increases, it is reasonable to speculate that in primary HTN, the central RAAS and Nrf2 
may interact in a way that increases SNA. To test the potential interaction and its role in 
regulating BP and autonomic function in HTN, we evaluated RVLM Nrf2 and oxidative 
stress in SynhACE2+/+ mice treated with chronic ICV-AngII infusion. We also assessed the 
effect of Nrf2 changes on AngII-induced HTN by either knocking-down Nrf2 in floxed mice 
or activating Nrf2 with SFN. 
Experimental Protocol 
Cell experiments were carried out using N2A neuron cells as described in Chapter III. One 
set of differentiated cells were treated with either the aCSF vehicle, AngII (30 or 100 nM), 
Ang1-7 (200 nM), the NOX inhibitor, APO, or SFN (10uM) for four hours or overnight. Cells 
then were subjected to nuclear fractionation to evaluate Nrf2 translocation. Another set of 
differentiated cells were transfected with hACE2-eGFP adenovirus to assess the effect of 
ACE2 overexpression on intracellular Nrf2 with or without AngII (100nM) stimulation. Cells 
were collected for western blot analysis. 
In vivo studies were performed on 3-month-old SynhACE2+/+, SynhACE2-/-, or wild type 
male mice on the C57BL background. For selective Nrf2 knockout in the RVLM, Nrf2f/f 
mice were subjected to bilateral microinjection of Lenti-Cre-GFP virus into the RVLM as 
described in Chapter III. The experimental design is shown in Fig 6.1 below.  
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All mice were instrumented with a radio telemetry unit (PA-C10; Data Sciences 
International Inc., Minneapolis, MN) with the catheter inserted into the left common carotid 
artery as described in Chapter III. Animals were allowed to recover for 1 week before 
hemodynamic recording. AP and HR were measured 2 hours daily from noon to 2:00 PM. 
A 24-hour recording was attained each week usually on a Saturday or Sunday. Following 
3 days of baseline recording, a cannula connected to a 7-day osmotic minipump (Model 
1002, Alzet, Inc. Cupertino, CA) with a pumping rate of 0.5ul/hour, was implanted into the 
right lateral ventricle to create a hypertensive model by chronic ICV infusion of AngII. The 
control group received aCSF. In order to avoid acute postoperative stress induced high 
BP, mice of all groups were equipped with minipumps filled with only aCSF for 1 week 
before switching to minipumps filled with different drugs. Each group received the 
assigned treatment with either AngII (100 ng/kg/min) or aCSF. In some experiments mice 
also received the Nrf2 activator, SFN (500ng/kg/min) to determine if this would abrogate 
the response to central AngII. SDRR and LF/HF were analyzed based on AP and HR 
recording data.  
During hemodynamic recording, mice were placed in a metabolic cage. After a 3-day 
adaptation period, 24-hour urine samples were collected daily. Mice were sacrificed 7 days 
after ICV infusion of different treatments. Brains were removed after euthanasia. 
Brainstem RVLM punches were used for western blot analysis. Some tissue was used for 
immunofluorescence staining. 
Results were analyzed by one-way or two-way ANOVA for repeated measures followed 
by Dunnett’s correction or Tukey’s test for multiple comparisons. All data are expressed 
as mean ± SE. Statistical analyses were performed using Prism8 (GraphPad Software, 
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Figure 6. 1 Animal experimental design. Figure 6.  1 Animal experimental design. 
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Results 
AngII induces Nrf2 nuclear translocation  
As a transcription factor, Nrf2 regulates phase 2 anti-oxidant enzyme expression by 
nuclear translocation when activated by intracellular ROS[184, 185].  However, many 
redox protective agents, such as β-lactoglobulin peptide (BRP2) or SFN were found to 
exert their anti-oxidant effects by also promoting Nrf2 nuclear translocation[186]. 
Therefore in our cell experiments the first question we wanted to clarify was the effect of 
AngII on Nrf2 behavior. Using N2A cells, we assessed Nrf2 translocation after AngII at 
different concentrations and different time periods, using SFN treatment as a positive 
control. Fig 6.2A demonstrates western blot data for Nrf2 in cytoplasmic and nuclear 
fractions after AngII stimulation. In the cytoplasmic fraction, although there were no 
statistical differences in Nrf2 between different conditions, in the nuclear fraction however, 
Nrf2 increased in a dose and time-dependent manner, with a peak level reached at 100nM 
AngII and 4 hour-treatment. GAPDH and Lamin-B were chosen for cytoplasmic and 
nuclear loading controls, respectively.  
To further investigate if this AngII-induced Nrf2 translocation was a result of oxidative 
stress, we treated with both Ang 1-7 and the NOX inhibitor, APO with AngII. As is shown 
in Fig 6.2B, both Ang 1-7 and APO significantly reduced nuclear Nrf2 translocation in 
response to AngII. Though specific ROS were not measured, these data indirectly 
suggested that AngII-induced Nrf2 translocation is very likely a cellular protective 
mechanism in response to oxidative stress due to AngII stimulation.   
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A. Cytoplasmic (light orange) and nuclear (dark orange) fractions were 
prepared from N2A cells treated with either vehichle, AngII(30, 100nM), or 
SFN (10uM) for either 2 hours or overnight. B. Nrf2 in nuclear fraction after 
treatment with Ang 1-7, AngII or APO. (n=3, *p<0.05) 
Figure 6.  2 Representative 
immunoblot for N f2 tra slocation 
in N2A 
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Effect of ACE2 on intracellular Nrf2 in response to AngII 
As discussed in earlier chapters, ACE2 is the key enzyme that converts AngII into Ang 1-
7 and possesses strong antioxidant properties. In order to determine the effect of ACE2 
on Nrf2 under AngII stimulation, we transfected N2A cells with hACE2-eGFP adenovirus 
to overexpress intracellular ACE2 prior to AngII treatment. Firstly, we evaluated ACE2 
virus transfection efficiency at different MOI (multiplicity of infection) and different 
incubation times. Fig 6.3A-B demonstrates ACE2 adenoviral transfection efficiency is 
positively corelated to viral titer (1-50 MOI) and incubation time (24-96 hour). Furthermore, 
we found that ACE2 overexpression increases whole cell Nrf2 shown in the western 
immunoblot (Fig 6.3B). Although the presence of either ACE2 or AngII upregulated Nrf2 
in N2A cells, when combined together, Nrf2 increase was attenuated, as is shown in Fig 
6.3B. Taken together, these data showed that Nrf2 responds to both AngII and ACE2 in 
N2A cells separately; co-existence of AngII and ACE2 though does not trigger a 






A. Whole cell ACE2 expression after Ad-hACE2-eGFP viral transfection at different 
titers. B. Whole cell Nrf2 protein in ACE2 overexpressed-N2A cells treated with or 
without AngII. Both ACE2 and AngII by themselves increase intracellular Nrf2; 
when combined together, the overall effect is decreased Nrf2 response compared 

























Figure 6. 3 Representative immunoblot for whole cell Nrf2 in Ad-hACE2-
eGFP transfected N2A cells. Figure 6.  3 Representative immunoblot 
for whole cell Nrf2 in Ad-hACE2-eGFP 
transfected N2A cells. 
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Nrf2 and NQO-1 are upregulated in the RVLM of SynhACE2+/+ mice 
In previous studies we showed that in animals with heart failure, there was a decreased 
expression of both ACE2 and Nrf2 in the RVLM [101, 187]. To further determine if there 
is a correlation between ACE2 and Nrf2, we measured Nrf2 protein in the RVLM of 
SynhACE2+/+ mice and their littermates treated with or without central AngII. We found 
that ICV AngII evoked an upregulation of Nrf2 in the RVLM compared to ICV aCSF in 
SynhACE2-/- animals (Fig 6.4A). This upregulation was inhibited by ACE2 overexpression. 
In order to determine if these changes in Nrf2 are specific to the RVLM, we also assessed 
tissues from the cerebral cortex and the hypothalamus, where no differences in Nrf2 levels 
were found. The antioxidant enzyme NQO-1 (Fig 6.4B) exhibited a similar trend as Nrf2.  
 
 




A. Nrf2 from RVLM punches showed an increase in response to ICV-AngII infusion, which was 
restored by ACE2 overexpression, RVLM NQO-1 was significantly increased by ACE2 
overexpression, which was attenuated in the ACE2+/+ /AngII group. C. Nrf2 was not different 







RVLM Nrf2 RVLM NQO-1
Visual Cortex 
Figure 6. 4 Representative immunoblot of Nrf2 and NQO-1 in the brain of synhACE2+/+ 







Figure 6.  4 Representative immunoblot of 
Nrf2 and NQO-1 in the brain of 
synhACE2+/+ with chronic central AngII 
infusion 
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Selective knockdown of Nrf2 in the RVLM enhances the pressor effect induced by 
central infusion of AngII 
As discussed in Chapter I, Nrf2 is a critical transcription factor for antioxidant defenses in 
many diseases [188-190]. In chronic heart failure, activation of Nrf2 decreases AT1R 
expression in the RVLM and evokes sympatho-excitation[191]. In healthy mice, selective 
deletion of Nrf2 in the RVLM induced HTN [120]. However, the response to ICV AngII is 
unknown in the face of Nrf2 deletion. Therefore, using Nrf2f/f  mice, we evaluated the 
impact of central AngII infusion in animals with RVLM Nrf2 deficiency to address the 
potential role of Nrf2 in AngII-induced neurogenic HTN. We selectively deleted Nrf2 in the 
RVLM. Immunofluorescence staining confirmed reduced Nrf2 in the RVLM following Cre-
GFP injection (Fig 6.5A-B). Figure 6.5C demonstrates micro-punches of RVLM subjected 
to western blotting which shows a significant reduction in Nrf2 protein (n=3, p<0.05). In a 
functional study, we showed that depletion of Nrf2 in the RVLM increased baseline 24 
hour day-night BP (mean ∆MAP= 21.0±1.8mmHg, n=3, p<0.05) (Fig 6.5D),  which is 
consistent with our previous data [120]. In addition, we also found that compared to the 
Nrf2f/f-GFP control group treated with AngII (mean ∆MAP= 9.0±1.7mmHg increase 
compared to baseline, n=3, p<0.05), Nrf2 deletion in the RVLM increased the MAP as high 
as 30.0 mmHg in Nrf2f/f-Cre mice, indicating an enhancement of the pressor effect of 







Nrf2 was selectively knocked down in the RVLM (A-B). RVLM Nrf2 protein quantification 
was validated by western immunoblot(C) (n=3, *p<0.05). 24 hour mean arterial BP at 
baseline (D) and 24 hour mean arterial BP 7 days post ICV-AngII infusion (E) showed 







Figure 6. 5 Representative immunofluorescence staining of Nrf2 knockdown in 
the RVLM 
Figure 6.  5 Representative immunofluorescence 






A. Chronic AngII infusion produced a significant increase in water intake during the 2-
week infusion period. This response was not enhanced by Nrf2 knock down using Cre 
virus delivered to the RVLM in Nrf2f/f mice.  B. Chronic AngII infusion produced an 
increase in urine output during the 2-week infusion period, which was not enhanced 
by Nrf2 knock down in the RVLM (n=5-7; *p < 0.05, **p<0.01).   
  
B. A
Figure 6. 6 Effect of RVLM Nrf2 knock down on central AngII-induced 
polydipsia and polyuria in Nrf2-floxed mice. 
Figure 6.  6 Effect of RVLM Nrf2 knock down on central AngII-induced polydipsia and polyuria in Nrf2-floxed mice. 
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Effects of Nrf2 deletion in the RVLM on water intake and urine output in response to icv 
AngII 
In Nrf2f/f mice that had Nrf2 knocked down in the RVLM we evaluated drinking and urine 
responses. We measured daily 24-hour water intake and urine volume and averaged the 
values over 7 consecutive days. In contrast to our expectations, Nrf2 deficiency 
suppressed the polydipsic and polyuric effect induced by ICV AngII infusion (Fig 6.6, n=5-
7). Prior to AngII treatment there was no difference between GFP- and Cre- treated Nrf2f/f 
groups).  
ICV-infusion of sulforaphane attenuates the pressor effect induced by central infusion of 
AngII 
To confirm a role of Nrf2 in mediating BP control in AngII-induced HTN, we upregulated 
central Nrf2 using icv infusion of SFN, a sulfur-containing compound that has been shown 
to possess potent antioxidant and anti-inflammatory properties through activation of Nrf2 
[192]. In this experiment, we infused AngII ICV with and without SFN to elucidate the 
protective effect of Nrf2. Nrf2 upregulation was assessed in the terminal experiment with 
RVLM punches, showing that both AngII and SFN increased Nrf2 individually (although 
SFN was non-significantly here), co-administration of the two seemed to have a 
synergistic effect on Nrf2 upregulation (Fig 6.7A). NQO-1 protein followed a similar trend 
as Nrf2 under corresponding treatment, but did not show statistical significance (Fig 6.7B) 
 Fig 6.8A demonstrates the functional data. After 3 days of baseline MAP recording, ICV-
AngII markedly increased BP in (red line and first half of black line). On day 6 SFN was 
administered with AngII in some animals that were treated with AngII alone. A significant 
decrease in BP was observed (second half of black line) (p<0.05). The group that was 
treated with SFN and AngII throughout the process exhibited a reduced increase in MAP 
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compared to the group treated with AngII alone (red) (p<0.05). SFN by itself did not alter 
BP (green line). Fig 6.8B are the 24 hour BP recording before and after ICV infusion, 
respectively. Although SFN attenuated the increase in AngII–induced BP most 
significantly during the day (p<0.05, right panel), the attenuation was not consistent 
throughout the 24-hour day-night cycle.  
Fig 6.8 C and D show SDRR and LF/HF calculated based on the MAP and HR recordings. 
After the first ICV-infusion of AngII, SDRR decreased and LF/HF increased suggesting 
increased sympathetic tone (red and blue groups in the two panels). SFN plus AngII 
infusion trended towards a blunting in the decrease in SDRR, however this did not reach 
statistical significance (blue). For LF/HF however, SFN significantly restored the alteration 
caused by ICV-AngII (grey and blue). These data suggest that SFN, at least, in part, 


























A. Co-administration of AngII and SFN ICV increased Nrf2 protein in RVLM.  B. No difference 






















Figure 6. 7 Immunoblot of Nrf2 and NQO-1 in RVLM after chronic ICV infusion of 
AngII, SFN, or AngII+SFN. 
Figure 6.  7 Immunoblot of Nrf2 and NQO-1 in RVLM after chronic ICV 
infusion of AngII, SFN, or AngII+SFN. 
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Figure 6. 8  ICV-SFN attenuates the pressor responses and SNA to central AngII. 
Figu







A. ICV-AngII infusion increases MAP which was attenuated with subsequent infusion 
of ICV-SFN. SFN alone did not alter BP. MAP was recorded 2 hours around noon 
every day(n=6, *p<0.05 compared to baseline; #p<0.05, &p<0.05 compared to AngII). 
B. 24 hour MAP in four groups before (left) and after (right) ICV infusion of the 
respective treatment (*p<0.05 compared to SFN, #p<0.05 compared to SFN+AngII, 
@p<0.05 compared to AngII then add ICV-SFN). C. SDRR (left) and LF/HF (right) 
during baseline and post-ICV infusion period. SFN showed some improvement in AngII 
induced reduction in HRV. (*p<0.05, #p<0.05, **p<0.01)  
 






Effects of sulforaphane on AngII-induced polydipsia  
To determine the effect of ICV-SFN on AngII-induced polydipsia and to also further assess 
the potential role of Nrf2 in fluid control, we assessed daily water intake and urine output. 
Fig 6.9 illustrates that ICV AngII increased drinking behavior by approximately 15 mL 
compared to baseline. Interestingly, although SFN reduced the BP increase by central 
AngII, it failed to suppress the polydipsia/polyuria effects, regardless of when SFN was 
administered.  
Figure 6. 9 Effects of ICV-SFN on central AngII- induced polydipsia and polyuria. 
A.          B.  
A. Chronic AngII infusion produced an overall increased water intake during the 1-week 
infusion period, addition of ICV-SFN showed similar increase in water intake(n=7; *p < 
0.05). B. Central AngII significantly increased urine output (**p < 0.01, n=7). Addition of 
ICV-SFN also has a significantly higher level of urine output compared to baseline (*p < 
0.05, n=7). SFN alone-group showed significantly lower daily urine volume but it did not 
further reduce urination compared to baseline.  
 
Figure 6.  9 Effects of ICV-SFN 
on central AngII- induced 
polydipsia and polyuria. 
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Discussion 
The study in this chapter explored the interaction between the RAAS and Nrf2. Our data 
demonstrated nuclear Nrf2 in neuronal N2A cells was increased in response to AngII 
stimulation in a time- and dose- dependent manner and provided direct evidence that 
intracellular Nrf2 responds to AngII. 100nM of AngII for 2 hours triggered the maximal 
increase in nuclear translocation, indicating the response is an acute process in these 
neuronal cells. In order to further confirm that Nrf2 translocation was a result of increased 
intracellular oxidative stress, we treated cells with APO to dampen the oxidative stress 
response to AngII. We found that APO effectively suppressed the Nrf2 response to AngII 
stimulation. However, Ang 1-7 (also shown to possess antioxidant activity) did not show 
the same effect as APO. It is possible that O2•− plays an important role in mediating the 
AngII-induced Nrf2 translocation process while Ang 1-7 may not work through O2•− 
inhibition, or Ang 1-7 being degraded by local enzymes such as neprilysin[193]. Other 
possibilities include optimal dosage of Ang 1-7 for the expected effect or variations in the 
expression of endogenous MasR on N2A cells[194].  
As a critical connection between AngII and Ang 1-7, ACE2 is a key molecule that is 
involved in this relationship. Neuro 2A cells overexpressing ACE2 showed that ACE2 by 
itself upregulated intracellular Nrf2 almost as much as AngII, and when treating the ACE2 
overexpressing cells with AngII blocked the Nrf2-inducing effect by AngII. These data were 
consistent with western blot data from RVLM tissue, which also showed a similar trend of 
Nrf2 changes in four treatment groups. These data suggest that Nrf2 upregulation is 
another possible quality of ACE2 that contributes to its anti-AngII effects. However, the 
exact mechanism by which ACE2 upregulates Nrf2 is not completely clear. In ACE2 viral-
transfected cells, AngII failed to trigger an increase in Nrf2. This is difficult to explain since 
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the Nrf2-upregulating effect of ACE2 should have a “synergistic” effect on Nrf2. It is 
possible that the consumption of AngII by ACE2 is too rapid to allow the latter to exert its 
Nrf2-inducing effect; or the degradation of AngII by ACE2 somehow overrides the Nrf2-
inducing effects of AngII or ACE2 alone. Importantly, significant differences in Nrf2 protein 
between the four treatment groups only existed in the RVLM among all the tissues tested, 
which included the visual cortex and hypothalamus. Taken together, this experiment 
indicated that both AngII and ACE2 induced an increase in intracellular Nrf2 protein and 
that ACE2 can inhibit this effect on Nrf2 exerted by AngII.  
To further understand the role of the interaction between the central RAAS and Nrf2 in 
modulating SNA we selectively knocked down Nrf2 in the RVLM using Nrf2 floxed mice 
and viral Cre delivery to evaluate their BP response prior to and after chronic ICV-AngII 
infusion. In Nrf2f/f mice treated with Cre virus, the baseline BP was significantly increased 
compared to mice treated with GFP virus. With AngII treatment, this increase was further 
enhanced. These results provide at least partial evidence that Nrf2 may attenuate 
sympathetic outflow. An interesting finding was the unaltered polydipsic and polyuric 
response by Nrf2 deletion to central AngII. Although Nrf2 has been shown to be a potent 
antioxidant factor that reduces sympathoexcitation in several studies[120, 195], it failed to 
exaggerate the drinking and urinary response to AngII. Possible reasons may be that 
although suppressing SNA, RVLM Nrf2 may not exert a major influence on those neurons 
projecting to the thirst control centers which are mostly located in forebrain regions.   
To further assess the role of central Nrf2 in regulating BP and SNA, we used SFN, a 
proven potent Nrf2 activator, in the ICV infusion in an attempt to upregulate central Nrf2. 
SFN is an extensively studied compound in translational medicine and can be found in 
most cruciferous vegetables[196]. RVLM Nrf2 protein upregulation was tested in terminal 
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studies by western blot. In SFN treated groups, Nrf2 was, in general, increased. 
Hemodynamic studies confirmed our hypothesis that ICV-SFN infusion blocked the 
pressor effects of central AngII reflected through both BP maintenance and HRV 
parameters. For BP assessment, not only did co-administration of SFN and AngII 
suppress the hypertensive response but adding ICV-SFN infusion after one-week of ICV-
AngII also significantly reversed the BP increase. Again, in accordance with our data from 
Nrf2 knockout mice, SFN did not affect the polydipsia or polyuria responses by AngII. We 
conclude that Nrf2 deletion has a major effect on BP and SNA but little influence on 
drinking behavior and therefore urine flow.  
In summary, in this study we showed that selective deletion of Nrf2  in the RVLM of mice 
resulted in an enhanced BP increase in response to central AngII infusion, and 
upregulation of Nrf2 by ICV-SFN resulted in attenuation of the pressor response to central 
AngII. These results provide evidence that central Nrf2 may possess anti-hypertensive 
properties, and this property may be at least one signaling pathway mediating the 























Therapy for cardiovascular disease, especially CHF and HTN has been relatively static 
for the past two decades. The use of agents that target the RAAS, β1-1 adrenergic 
blockers, diuretics and in some cases vasodilators are the primary pharmacological 
agents that are used to treat these disorders. While effectively lowering morbidity and 
mortality the degree of CHF and HTN are still unacceptably high. There is a desperate 
need to develop novel therapies that target unexplored mechanisms for CHF and HTN. 
While centrally acting drugs such as clonidine and moxonidine have been used they are 
associated with negative side effects and are difficult to regulate their dose – response 
relationships[197]. Because both disorders are associated with oxidative stress and 
increases in sympathetic outflow it is reasonable to evaluate therapies that have been 
shown to affect both mechanisms. 
The two agents studied in this dissertation have been shown to reduce oxidative stress in 
both CHF and HTN [74, 120, 185, 198]. ACE2 or ACE2 activation and Ang 1-7 have been 
used to treat HTN in animal models[171, 199-201]. The mechanism for the protective 
effects of these therapies has been assumed to be a reduction in AngII peptide and both 
a vasodilator and sympatho-inhibitory effect of Ang 1-7 mediated, in part, through a 
reduction in oxidative stress [202, 203] primarily in the peripheral circulation. According to 
ClinicalTrials.gov there are 13 clinical trials where modulation of ACE2 is or has recently 
been investigated for the treatment of HTN, stroke, and the metabolic syndrome. Similarly 
there are 56 trials where Nrf2 activation is being used to treat a variety of diseases 
including cardiovascular disease. None of these trials specifically target the central 
nervous system although areas of the CNS may be involved in the positive actions of 
ACE2 and Nrf2 activation. 
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The results presented here suggest that activation or overexpression of both ACE2 and 
Nrf2 reduce sympathetic outflow in HTN and CHF when the RVLM is targeted. What is 
less clear from this work is how this could be used in a translational way for human disease. 
Systemic administration of ACE2 or Nrf2 activators will, of course, target all tissues.  It is 
highly likely that small molecule activators such as diminazene aceturate (DIZE; [204]), 
sulforaphane[205] and dimethyl fumarate[206] are likely to gain entry through the blood 
brain barrier or via areas with no blood brain barrier such as the circumventricular 
organs[207]. Therefore, systemic administration may also target the CNS and potentially 
the sympatho-regulatory areas in the brain. In addition, new modalities of drug delivery 
have been developed using a variety of nanoparticles and extracellular vesicles for 
antioxidant therapy [208-212]. While animal studies have been positive, it is not clear how 
to specifically target these particles to the CNS in humans. 
While targeting each of these molecules individually may have beneficial effects the 
studies described in this dissertation do not allow us to define the role of ACE2 in Nrf2 – 
mediated reduction in ROS in CHF or HTN. Figure 7.1 provides an overview of the 
potential interactions between these pathways. We suggest that any intervention that 
augments ACE2 and Nrf2 will have a beneficial effect in the settings of CHF and HTN. 
This work provides supportive evidence for focusing on ACE2 and Nrf2 in modulating the 
sympathetic nervous system in disease. 
 
 





















The diagram is based on data demonstrated in part from this thesis. AngII is a known 
pro-oxidant and pro-inflammatory peptide that is rapidly converted to Ang 1-7 by the 
action of ACE2. Through the AT1R it activates Nox2 which results in increased levels 
of superoxide in the cytosol. AngII, through increased levels of ROS, activates both Nrf2 
and  NFkB (not studied in this thesis). Both transcription factors are released from their 
protein inhibitors in the cytosol and translocate to the nucleus where they compete for 
binding to the creb binding protein (CBP). Increased inflammation in response to high 
levels of AngII may result in reduced Nrf2 levels. In addition, increased ubiquitination of 
Nrf2 in heart failure and in inflammatory states contributes to the reduced Nrf2 in CHF 
and HTN. Overexpression of ACE2 reduces the levels of AngII, thus decreasing ROS 
generation and sympatho-excitation. Decreases in AngII mediated inflammation may 
also result in augmented Nrf2 levels and thus increases in antioxidant enzyme 
transcription. Other potential mechanisms not studied here are the role of nitric oxide 
(NO) in scavenging ROS due to increased Ang 1-7. It does not appear that 
overexpression of ACE2 in the brain reduces AngII induced HTN by augmenting levels 
of Ang 1-7 but more likely by reducing central AngII levels. There remains a question 
as to a direct effect of ACE2 overexpression on Nrf2 in these cardiovascular diseases. 
 
Figure 7.1  Overview of the mechanisms and potential involvement of ACE2 and 
Nrf2 in the regulation of sympathetic outflow in neurons from the RVLM in the 
setting of CHF and HTN in response to increased central AngII.  
Figure 7 1 Overview of the mechanisms and potential involvement of 
ACE2 and Nrf2 in the regulation of sympathetic outflow in neurons 
from the RVLM in the setting of CHF and HTN in response to 
increased central AngII. 
Figure 7.  1 Overview of the 
mechanisms and potential 
involvement of ACE2 and Nrf2 in the 
regulation of sympathetic outflow in 
neurons from the RVLM in the 
setting of CHF and HTN in response 


















The present thesis examined the putative sympatho-inhibitory properties of Nrf2 and 
ACE2 in the CNS and potential interplay between the RAAS and Nrf2 in regulating BP. 
The findings in this work suggest:  
1). Nrf2 expression in the RVLM of mice with coronary artery ligation-induced CHF 
was significantly lower compared to sham mice. Overexpression of Nrf2 in the 
RVLM significantly reduced SNA and improved arterial baroreflex function in CHF 
mice; 
2). Central ACE2 possesses anti-hypertensive, antioxidative, and sympatho-
inhibitory effects and modifies the response to chronic central AngII infusion. The 
data suggest that the anti-hypertensive effects of ACE2 overexpression are most 
likely through an Ang 1-7 independent mechanism; 
3). Nrf2 may at least partially mediate the sympatho-inhibitory effect of ACE2 in 
response to central AngII induced HTN.  
 
Although we have made every effort to take a comprehensive approach in these studies, 
we acknowledge that there are limitations. In our HTN model, despite the fact that chronic 
ICV-AngII infusion evoked a sustained increase in AP it is not clear where AngII is working 
since the AT1R is expressed throughout the brain. The non-specificity in targeting specific 
regions of autonomic control is a major limitation. Even though we focused on an important 
sympatho-regulatory nucleus (the RVLM), other nuclei in the brainstem and hypothalamus 
need to  be considered in future studies, given the complexity of projections between each 
area. 
In a previous study, CHF animals exhibited a downregulation of Nrf2 in the RVLM and 
increased sympathoexcitation [213, 214]. Therefore, it is natural to assume that chronic 
RAAS activation in the CNS, which is also correlated with sympathoexcitation, would be 
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associated with downregulation of Nrf2 as well. However, in our model of central AngII 
induced HTN, we found that after two weeks of HTN, Nrf2 in the RVLM was markedly 
increased compared to their control littermates. One possible reason for this finding could 
be differences in acute-versus-chronic phases in terms of Nrf2 activation. In the case of 
CHF, it usually takes 4 to 6 weeks to develop a chronic state of heart failure. In response 
to AngII infusion however, Nrf2 was mobilized as an acute defense mechanism in 
response to AngII-induced oxidative stress, which was what we observed after  2 weeks 
of ICV AngII infusion.  It may be possible that with longer central AngII infusion, Nrf2 
protein may be reduced as is seen in CHF. Therefore, further studies of the time course 
of Nrf2 changes in the RVLM during AngII infusion is important for a thorough 
understanding of these phenomena. 
Further questions worth discussion is whether the changes of Nrf2 under circumstances 
in the above chapters are the direct result of Nrf2 translocation, expression, or both. Nrf2 
exists in the cytoplasm in a sequestered form before it is activated and translocates to the 
nucleus. Despite Keap1 dependent regulation, there are multiple Keap1 independent 
modifications that affect Nrf2 protein and activation, including phosphorylation, acetylation, 
and epigenetic alteration in order to “fine tune” the Nrf2 signaling pathways [215]. In our 
N2A cell study, we demonstrated that nuclear Nrf2 increases in response to AngII 
stimulation in a dose-dependent manner. In our molecular studies using RVLM punches 
we only exmined the protein changes for Nrf2. However, to determine if there are changes 
in Nrf2 expression or degradation, further evaluation at the message level and 
ubiquitination should be carried out in the future.   
In terms of the drinking and urine flow findings, we did not see a significant impact of Nrf2 
on AngII induced polydipsia and polyuria. Fluid retention is found in a large proportion of 
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CHF and HTN patients[216, 217], and is thought to be commonly attributed to disease 
exacerbation and therapy resistance. The periventricular anteroventral third ventricle 
(AV3V) region, containing the MnPO, OVLT, and AV3V in the brain is critically involved in 
the maintenance of normal body fluid balance and distribution. Buggy et al. demonstrated 
that ablation of AV3V region in rats abolished the drinking responses elicited by ICV 
injections of AngII [218]. In the current study, we showed that chronic ICV infusion of AngII 
markedly increased drinking behavior as expected. Although manipulating Nrf2, either by 
viral injection in the RVLM or by SFN infusion, significantly affected BP changes caused 
by AngII, the drinking and urine responses were not altered. On one hand, the MnPO of 
the hypothalamus could respond to AngII infusion as a thirst-generating stimulus [219], 
and this response may be minimally affected by oxidative stress. Alternatively, deletion of 
Nrf2 in the RVLM may trigger some inhibitory signaling towards the AV3V region, thus 
failing to enhance the polydipsia induced by AngII infusion. This is conjecture and either 
way further studies need to be done to determine the differences in BP regulation and 
drinking behavior in our model.   
The mouse RVLM is an extremely small nucleus that requires a good deal of skill to be 
localized. We feel confident that we carried out precise targeting and delivered the 
microinjections into mouse RVLM. However, there is some variability in targeting and in 
punching out tissue for biochemical analysis. Surrounding tissue is undoubtedly obtained 
outside of the area of interest. In hindsight laser capture microscopy would have been 
useful to better define tissue borders. We did however examine GFP expression outside 
of the RVLM and saw no expression.  
To further examine effect of Nrf2 activation on BP, we used the widely used Nrf2 activator, 
SFN. Although this method compromised the RVLM specificity compared to viral 
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microinjection. In addition to activating Nrf2 nuclear translocation, SFN may possess some 
direct antioxidant properties via a Nrf2-independent mechanism [220, 221]. Nevertheless, 
the observation of effects in the RVLM and a consistent physiological outcome on BP in 
response to AngII made this method a good comparison to direct viral injection of cre in 
Nrf2f/f mice.    
In conclusion, chronic cardiovascular diseases such as CHF and primary HTN are 
cardiovascular problems characterized by sustained sympathoexcitation and blunted 
baroreflex sensitivity. The central RAAS, especially the two functionally opposing 
components of ACE/AngII/AT1R and ACE2/Ang 1-7/Mas R, play a critical role in 
influencing SNA through modulating oxidative stress. Nrf2, an important antioxidant 
transcription factor, has been shown to reduce sympathetic tone in these two conditions. 
These studies indicate the likely relationship between ACE2 and Nrf2 in regulating SNA 
in HTN and that upregulation or activation of Nrf2 in CHF may be a beneficial therapeutic 
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